Antibodies against glucocorticoid-induced TNFR-related (GITR) proteins and uses thereof
By modifying the human IgG1 Fc region of anti-GITR antibodies, the inhibitory FcγRIIB binding and the activation of FcγRIIA and FcγRIIIA binding was solved, and significant anti-tumor activity and long-term immune effects were achieved. .
Patent Information
- Application Number
- CN202380027936.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-14
- Publication Date
- 2024-11-12
AI Technical Summary
Existing anti-GITR antibodies have encountered difficulties in clinical transformation and have failed to reproduce their significant therapeutic potential in preclinical models in clinical trials, especially as their interaction with human FcγR is not adequately resolved, resulting in treatment Sexual antitumor activity failed to meet expectations.
An antibody containing the modified human IgG1 Fc region was designed to employ glycoengineering and protein engineering strategies such as defucosylation and specificity by reducing binding to inhibitory FcγRIIB and enhancing binding to activated FcγRIIA and FcγRIIIA. Amino acid substitution (such as G236A, A330L, I332E) to improve the anti-tumor activity and long-term immune effect of the antibody.
This antibody significantly improves growth control and survival of tumors, enhances the anti-tumor response of the immune system by activating dendritic cells and producing proinflammatory cytokines, and shows that it is not dependent on GITR receptor activation Anti-tumor immune activity reduces the Treg frequency in TME.
Smart Images

Figure BDA0005044306860000481 
Figure BDA0005044306860000491 
Figure HDA0005044306870000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of immunotherapy and relates to engineered antibodies, polynucleotide sequences encoding them, and pharmaceutical compositions and therapeutic uses. Background Art
[0002] Cancer treatment has made significant progress in the past decade, driven by immunomodulatory therapies that enhance host anti-tumor defense. Specifically, immune checkpoint inhibitors such as monoclonal antibodies (mAbs), which target the immune system rather than directly recognize tumors, have been shown to induce durable responses in treated patient subpopulations across multiple tumor types (Ribas, A. and Wolchok, JD, Cancer immunotherapy using checkpoint blockade, Science 80-, 359, 1350–1355, 2018). Based on their means of inducing anti-tumor immune responses, these antibodies can be divided into two groups: (i) agonistic mAbs that stimulate activated co-regulatory receptors in the immune synapse (Mayes, A. et al., The promise and challenges of immune agonist antibody development in cancer, Nature Reviews Drug Discovery, 17, 509–527, 2018), and (ii) antagonistic mAbs that block inhibitory signaling pathways in the immune synapse, thereby attenuating regulatory (inhibitory) mechanisms (Sharma et al., The future of immune checkpoint therapy, Science 348, 56–61, 2015).
[0003] Antibodies consist of two structural regions: a variable fragment (Fab), which mediates antigen binding, and a constant fragment (Fc), which mediates downstream effector functions by interacting with Fc receptors on (innate) immune cells or proteins of the complement system.
[0004] Fcγ receptors (FcγR) belong to the immunoglobulin superfamily and share many structural and functional properties. According to the presence of intracellular activation (immunoreceptor tyrosine-based activation motifs, ITAM) or inhibition (immunoreceptor tyrosine-based inhibition motifs, ITIM) signal transduction motifs, FcγR can be classified as activating or inhibitory. Three activating FcγRs are expressed in mice (FcγRI, FcγRIII and FcγRIV) and humans (FcγRI, FcγRIIA and FcγRIIIA), and a single inhibitory FcγRIIB is expressed in both species. Each FcγR has a different cellular expression pattern. The binding of activating FcγR induces effector mechanisms, such as antibody-dependent cellular toxicity (ADCC), phagocytosis and the production of proinflammatory cytokines. Signal transduction by inhibitory receptor FcγRIIB leads to negative functions, such as the inhibition of inflammatory immune responses. The binding of activating or inhibitory FcγR by the Fc domain of the antibody is determined by the IgG subclass and the Fc glycan composition (Pincetic, A. et al., Type I and type II Fc receptors regulate innate and adaptive immunity, Nat. Immunol. 15, 707–716, 2014).
[0005] Dendritic cells are a heterogeneous population of antigen-presenting cells that infiltrate tumors. Although dendritic cells play a key role in initiating and maintaining local immunity, their function is often attenuated or inhibited by factors encountered in the tumor microenvironment. In addition, populations of dendritic cells with immunosuppressive activity are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. The activation of dendritic cells plays a key role in initiating anti-tumor T cell immunity and therefore represents a major therapeutic target for cancer immunotherapy (Whily et al., Dendritic Cells and Cancer: From Biology to Therapeutic Intervention, Cancer 11, 4, 521.2019).
[0006] To date, the main principle guiding the design and development of antibodies is the need to engineer their Fab domains to enhance their effects on specific receptor targets on immune cells. However, recent in vivo findings have highlighted the importance of the Fc domain in enhancing the potency of checkpoint antibody inhibitors by recruiting additional types of immune cells expressing activating and / or inhibitory FcγRs (Dahan, R. et al., Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement, Cancer Cell 29, 820–831, 2016; Vargas, FA et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell 33, 649–663.e4, 2018).
[0007] Fc engagement of activating FcγRs is required for the induction of antibody effector functions, such as the elimination of intratumoral regulatory T cells (Tregs) by anti-CTLA4 (cytotoxic T lymphocyte-associated protein 4 / CD125), anti-OX-40 (CD134) or anti-4-1BB antibodies (Bulliard, Y. et al., OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to anti-tumor efficacy, Immunol. Cell Biol. 92, 475–480, 2014; Buchan, SL et al., Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function). Another Fc binding can induce FcγR in the tumor microenvironment (TME). +Reprogramming of myeloid cells and natural killer (NK) cells, for example, by anti-PD-L1 (programmed death ligand 1) and anti-CD73 mAbs (Dahan, R. et al., Activating Fcγ receptors contribute to the anti-tumor activities of immunoregulatory receptor-targeting antibodies, J. Exp. Med. 210, 1685–1693, 2013; Dahan, R. et al., FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1 / PD-L1 Axis, Cancer Cell 28, 285–295, 2015; and Dahan, R. and Ravetch, JV, Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Enhancement of Fc Receptor Binding. Pathways for Immunotherap: Potentiation by Fc receptor Engagement), Cancer Cell 30, 2016).
[0008] In contrast, the binding of inhibitory FcγRIIB provides an inert scaffold for antibody cross-linking to enhance the activity of agonistic mAbs, primarily those targeting tumor necrosis factor receptors (TNFRs), such as anti-CD40 mAbs (Li, F. and Ravetch, JV, Anti-tumor activities of agonistic anti-TNFR antibodies require differential FcRγIIB co-engagement in vivo, Proc. Natl. Acad. Sci., 110(48), 19501-6, 2013). Thus, agonistic mAbs can act through multiple mechanisms in vivo (e.g., TNFR activation and Treg depletion), which can synergize their activities for optimal therapeutic efficacy. Therefore, choosing an appropriate scaffold for each antibody (composed of IgG subtypes or Fc region variants that selectively bind to or avoid specific FcγR pathways) is extremely important for achieving optimal anti-tumor activity.
[0009] One of the above immune checkpoint molecules is glucocorticoid-induced TNFR-related (GITR, also known as TNFRSF18 and CD357) protein. GITR is a member of the cell surface TNF receptor superfamily, constitutively expressed at high levels on regulatory T cells (Tregs), and expressed at low levels on naive and memory T cells (G. Nocentini, C. Riccardi, GITR: a modulator of immune response and inflammation, Adv Exp Med Biol, 647 156-173, 2009).
[0010] GITR triggers co-activation of effector T lymphocytes and regulates regulatory T cell (Treg) activity. GITR is activated by GITR ligand (GITRL) expressed primarily on antigen presenting cells (APCs). GITR activation increases resistance to tumor and viral infections, participates in autoimmune / inflammatory processes, and regulates leukocyte extravasation. Therefore, GITR is an attractive target for immunotherapy due to its ability to promote effector T cell function and impede regulatory T cell suppression.
[0011] The activation of T cells by various different stimuli rapidly increases GITR expression on both regulatory T cells (Treg) and effector T cells (Teff) within 24 hours (LTKrausz et al., GITR-GITRL system, a novel player in shock and inflammation, Scientific World Journal, 7 533-566, 2007). FoxP3, a key regulatory protein for Treg development and function, promotes high-level expression of GITR in mature T cells, while in activated T cells, canonical NFκB signaling induces GITR expression, indicating that cell types regulate expression intrinsically (Y. Zhan et al., Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT, J Immunol, 181 5405-5413, 2008).
[0012] After activation, low to moderate levels of GITR were also detected on innate immune cells (S. Hanabuchi et al., Human plasmacytoid predendritic cells activate NK cells throughglucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL), Blood, 107 3617-3623, 2006). Among innate cell types, the highest induction was observed on activated natural killer (NK) cells, with levels comparable to GITR expression on activated T effector (Teff) cells. Only moderate levels were observed on activated macrophages and dendritic cells (DCs) (DL Clouthier, TH Watts, Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection, Cytokine Growth Factor Rev, 25 91-106, 2014).
[0013] The high level of GITR expression in activated Tregs is an important distinction that became more apparent during in vivo assessment of GITR regulation. Numerous studies have reported that tumor-infiltrating Treg cells expressing GITR are present in tumors such as non-small cell lung cancer (NSCLC), renal cell carcinoma, melanoma, glioblastoma, colorectal cancer, breast cancer, and ovarian cancer (Curiel, T. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med 10, 942–949, 2004; Zhu et al., Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types, Mod Pathol 33, 1753–1763, 2020; Vence L et al., Characterization and Comparison of GITR Expression in Solid Tumors, Clin Cancer Res. 2019, 25(21), 6501-6510).
[0014] It was found that anti-mouse GITR antibodies rely on FcγR-mediated Treg depletion and CD8 T cell proliferation to obtain anti-tumor activity (D. Coe et al., Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy, Cancer Immunol Immunotherapy, 59, 1367-1377, 2010).
[0015] Anti-GITR agonist antibodies, as monotherapy or in combination with other immunotherapies, show significant therapeutic potential by enhancing effector T cells and suppressing Treg responses in the tumor microenvironment (TME), as demonstrated in preclinical models (ADCohen et al., Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation, PLoS One. 5, 2010; DASchaer, J. et al., Modulation of GITR for cancer immunotherapy, Curr. Opin. Immunol. 24217-224 2012; L. Lu et al., Combined PD-1 blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model and synergizes with chemotherapeutic drugs (Combined PD-1blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model and synergizes with chemotherapeutic drugs (Combined PD-1blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model and synergizes with chemotherapeutic drugs (Combined PD-1blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model and synergizes with chemotherapeutic drugs (Combined PD-1blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model and synergizes with chemotherapeutic drugs (Combined PD-1blockade and GITR triggering induces a potent anti-tumor immunity in a murine cancer model in murine cancer models and synergizes with chemotherapeutic drugs), J Transl Med, 12, 36-47, 2014; Zappasodi R et al., Rational design of anti-GITR-based combination immunotherapy, Nat Med. 2019, 25(5), 759-766).However, its clinical translation has encountered major obstacles: promising preclinical activity has not yet been reproduced in clinical trials (Tran B. et al., Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors, J Immunother Cancer. 2018, 6(1), 93; Siu LL et al., Preliminary results of a phase I / II a study of BMS-986156, glucocorticoid-induced tumor necrosis factor receptor–related gene(GITR) agonist, alone and in combination with nivolumab in patients with advanced solid tumors). nivolumab in patients with advanced solid tumors), J Clin Oncol. 2017, 35(15_suppl), 104).
[0016] The anti-mouse GITR (mGITR) agonist antibody called DTA-1 is an IgG2b rat antibody that is most widely used in research (J. Shimizu et al., Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance, Nat Immunol. 3, 135-142, 2002). Currently, only a few antibodies are in preclinical or clinical (Phase I / II) trials, such as MK-4166 (US8709424) of Merck & Co Inc., ragavulimab (US10155818) of Incyte Corp., REGN-6569 (US10738126) of Regeneron Pharmaceuticals Inc., PTZ-522 (US2018208665) of Potenza Therapeutics Inc., GWN-323 (US10662247) of Novartis AG, and BMS-986156 (US9228016) of Bristol-Myers Squibb Co. WO2015187835 discloses an anti-human GITR (hGITR) antibody with an engineered Fc region, which has improved binding to FcγRIIB and improved ADCC activity.
[0017] US Patent No. 7812135, US Patent No. 1121358 and US2019010241 disclose specific mAbs against human GITR.
[0018] U.S. Patent No. 9040041 discloses a method for enhancing the activation of antibody-dependent cellular phagocytosis (ADCP) by an antibody comprising an engineered human Fc. The protein targets of the engineered antibody are Ep-CAM, CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2 / neu, EGFR, IGF-1R, EpCAM, MUC1, GD3, CEA, CA125, HLA-DR, MUC18, and prostate-specific membrane antigen (PMSA).
[0019] WO2019 / 125846 discloses human IgG Fc region variants specific for tumor antigen sLeA, which have improved effector functions and higher binding affinity for hFcγRIIA, hFcγRIIIA and hFcγRIIB. One of the antibodies, hIgG1-G236A / A330L / I332E (GAALIE), has enhanced binding affinity for activating hFcRIIA and hFcRIIIA, has lower binding to inhibitory FcγRIIB, and also exhibits enhanced ADCC activity.
[0020] Weitzenfeld P. et al. disclosed carbohydrate-targeted antibodies comprising a combination of specific mutations in the Fc domain, which result in enhanced affinity for two activating hFcγRs, hFcγRIIA and hFcγRIIIA, while reducing binding to the inhibitory receptor hFcγRIIB (Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways, J. Clin. Invest, 129, 3952–3962, 2019).
[0021] US Patent No. 10479838 discloses a specific antibody that binds to CD40, comprising an Fc region modified to enhance the specificity of binding to FcγRIIB.
[0022] WO2003035835 discloses a cell line with reduced ability to attach fucose to N297-linked carbohydrates, resulting in hypofucosylation of expressed antibodies, wherein about 80-100% of the glycoproteins contain mature core carbohydrate structures lacking fucose. The produced antibodies bind to human FcγRIIIA and have increased ADCC activity relative to fucosylated antibodies. One of the disclosed antibody variants has increased binding to FcγRIIA and FcγRIIIB.
[0023] The consequences of the interaction of human FcγRs with anti-human GITR antibodies have not been fully resolved, and there remains an unmet need for suitable IgG scaffolds to enhance the antitumor activity of therapeutic anti-GITR antibodies by selectively binding to Fcγ receptors in the TME. Summary of the invention
[0024] According to some embodiments, the present invention provides antibodies that bind to glucocorticoid-induced TNFR-related (GITR) proteins, which have improved therapeutic anti-tumor activity compared to previously known antibodies against the protein. The present invention provides anti-GITR antibodies comprising Fc modifications, which result in increased binding to at least one of the activating receptors FcγRIIA and FcγRIIIA, and optionally reduced binding to the inhibitory FcγRIIB receptor. Unexpectedly, it was found that the Fc-modified antibodies of the present invention, although having a high binding rate to FcγRIIA and / or FcγRIIIA relative to FcγRIIB and thus being unable to participate in FcγRIIB-mediated antibody cross-linking, induce enhanced in vivo anti-tumor effects and long-term anti-tumor immunity. Antibodies with the same Fab region and a lower binding rate to FcγRIIA and / or FcγRIIIA relative to FcγRIIB fail to induce anti-tumor effects and long-term anti-tumor immunity.
[0025] The present invention provides a therapeutic antibody that binds to GITR through the Fab region with high affinity and specificity, and binds to the activating FcγRIIA and FcγRIIIA receptors through the Fc region, and has a relatively low binding affinity to the inhibitory receptor FcγRIIB. The antibody of the present invention is characterized in that it has a modified human IgG1 Fc region, wherein the modified human IgG1 Fc region comprises a substitution of a glycine residue at position 236 by an alanine residue (G236A), and at least one further modification selected from the following: a reduction in glycosylation content (e.g., defucosylation), a substitution of alanine at position 330 by leucine (A330L), and a substitution of isoleucine at position 332 by glutamic acid (I332E). The numbering of amino acid residues in the Fc region is carried out according to the EU index.
[0026] Thus, according to one aspect, the present invention provides an antibody that specifically binds to GITR, or a composition comprising at least one such antibody, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), wherein the antibody has an improved binding ratio to (RIIA and / or RIIIA) / RIIB compared to an antibody having the same Fab and a parental non-modified human IgG1 Fc.
[0027] According to some embodiments, the human IgG1 Fc region modification results in an improved binding ratio of the antibody to RIIA / RIIB, RIIIA / RIIB and (RIIA+RIIIA) / RIIB.
[0028] According to some embodiments of this aspect, the invention provides an antibody that specifically binds to GITR, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 Fc region, wherein the modified human IgG1 Fc region is selected from:
[0029] i. a human IgG1 Fc region comprising an asparagine residue (N) at position 297, a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) G236A, and a fucosylation content of up to about 40% in all glycan structures (referred to herein as afuco-G236A); and
[0030] ii. a human IgG1 Fc region comprising the following amino acid substitutions: substitution of the glycine residue at position 236 by an alanine residue (G236A), substitution of the alanine residue at position 330 by a leucine residue (A330L), and substitution of the isoleucine residue at position 332 by a glutamic acid residue (I332E) (referred to herein as GAALIE).
[0031] Therefore, according to some embodiments, the present invention provides an isolated defucosylated antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), which comprises an asparagine residue (N) at position 297 and a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) G236A (referred to herein as afuco-G236A).
[0032] According to other embodiments, the present invention also provides an antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), wherein the modified human IgG comprises the following amino acid substitutions: substitution of a glycine residue at position 236 by an alanine residue (G236A), substitution of an alanine residue at position 330 by a leucine residue (A330L), and substitution of an isoleucine residue at position 332 by a glutamic acid residue (I332E) (referred to herein as GAALIE).
[0033] According to some embodiments, the GITR is human GITR (hGITR).
[0034] According to some embodiments, the antibody is a humanized antibody.
[0035] According to some embodiments, the antibody is a chimeric antibody.
[0036] Any binding site, hypervariable region (HVR) or Fab of an antibody that specifically recognizes GITR, particularly hGITR, can be used to generate the IgG1-Fc region modified antibodies of the present invention. This includes agonist, non-agonist and mixed agonist / non-agonist antibodies, as well as antibodies that do not elicit a response or mediate any activity associated with binding to hGITR after binding to hGITR. In some embodiments, binding to hGITR on T cells is only used to target the antibodies of the present invention to the desired location of the immune synapse, while the modified Fc region mediates its activity on cells expressing FcγR.
[0037] According to some embodiments, the Fab of the anti-hGITR antibody is derived from an agonist antibody that elicits GITR activation mediated by MAPK signaling.
[0038] According to some embodiments, the Fab of the anti-hGITR antibody is derived from a non-agonist antibody.
[0039] According to some embodiments, the Fab of the anti-hGITR antibody comprises a set of 6 CDR sequences of an antibody specific for human GITR.
[0040] According to some embodiments, the antibody comprises a set of 6 CDR sequences, wherein the set is selected from:
[0041] i. A heavy chain (HC) CDR1 comprising the sequence GFSLSTSGMG (SEQ ID NO: 1), a HC CDR2 comprising the sequence IWWDDDK (SEQ ID NO: 2), a HC CDR3 comprising the sequence ARTRRYFPFAY (SEQ ID NO: 3), a light chain (LC) CDR1 comprising the sequence QNVGTN (SEQ ID NO: 4), a LC CDR2 comprising the sequence SAS or the sequence SAST (SEQ ID NO: 5), and a LC CDR3 comprising the sequence QQYNTDPLT (SEQ ID NO: 6);
[0042] ii. a HC CDR1 comprising the sequence SYGMH (SEQ ID NO: 7), a HC CDR2 comprising the sequence VIWYEGSNKYYADSVKG (SEQ ID NO: 8), a HC CDR3 comprising the sequence GGSMVRGDYYYGMDV (SEQ ID NO: 9), a LC CDR1 comprising the sequence RASQGISSALA (SEQ ID NO: 10), a LC CDR2 comprising the sequence DASSLES (SEQ ID NO: 11), and a LC CDR3 comprising the sequence QQFNSYPYT (SEQ ID NO: 12); and
[0043] iii. HC CDR1 comprising the sequence GYTFTRYW (SEQ ID NO: 25), HC CDR2 comprising the sequence IYPGDGDT (SEQ ID NO: 26), HC CDR3 comprising the sequence ARNPLTTATAWFVY (SEQ ID NO: 27), LC CDR1 comprising the sequence ENIYSN (SEQ ID NO: 28), LC CDR2 comprising the sequence AAT, and LC CDR3 comprising the sequence QHFWGPPWT (SEQ ID NO: 29).
[0044] Each option represents a separate embodiment of the present invention.
[0045] According to some embodiments, the afuco-G236A antibody comprises a human IgG1 heavy chain constant region comprising the following sequence:
[0046] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL A GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 13, where the G236A substitution is underlined).
[0047] According to some embodiments, the defucosylated G236A antibody comprises a human kappa light chain constant region comprising the following sequence:
[0048] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC (SEQ ID NO: 14).
[0049] According to some embodiments, the afuco-G236A antibody comprises a heavy chain comprising the sequence set forth in SEQ ID NO:13 and a light chain comprising the sequence set forth in SEQ ID NO:14.
[0050] According to some embodiments, the GAALIE antibody (Fc region substitutions G236A, A330L and I332E) comprises the following heavy chain constant region sequence:
[0051] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL A GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP L P E EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 15, wherein the substitutions are underlined).
[0052] According to some embodiments, the GAALIE antibody comprises a heavy chain comprising the sequence set forth in SEQ ID NO:15 and a light chain comprising the sequence set forth in SEQ ID NO:14.
[0053] According to some embodiments, the Fc region modification results in enhanced activation of dendritic cells (DCs), production of inflammatory cytokines, or both.
[0054] According to some embodiments, the Fc region modification does not result in enhancement of ADCC activity.
[0055] According to some embodiments, the Fc region modification results in activation of dendritic cells, leading to upregulation of DC activation markers, and without enhancement of ADCC.
[0056] Conjugates comprising the above anti-hGITR antibodies are also within the scope of the present invention. These conjugates may include a moiety such as a detectable probe or toxin attached to the anti-GITR antibody of the present invention. The moiety may be attached to any part of the antibody as long as it does not interfere with binding to hGITR and binding to human FcγRIIA and FcγRIIIA.
[0057] According to another aspect, the present invention also provides a polynucleotide sequence encoding at least one chain of the above-mentioned antibody that specifically binds to hGITR.
[0058] According to some embodiments, the antibody encoded by the polynucleotide sequence of the present invention comprises a variable region (Fab) that recognizes hGITR and a modified human IgG1 constant region (Fc), wherein the modified human IgG1 Fc region is selected from:
[0059] i. a human IgG1 Fc region comprising N at position 279 and comprising the substitution G236A; and
[0060] ii. A human IgG1 Fc region comprising the amino acid substitutions G236A, A330L and I332E (referred to herein as GAALIE).
[0061] According to some embodiments, the polynucleotide sequence encodes at least one chain of an antibody with high affinity and specificity for hGITR, wherein the antibody comprises a modified IgG1 Fc region comprising a substitution of amino acid residue glycine at position 236 by an alanine residue (G236A), a substitution of amino acid residue alanine at position 330 by a leucine residue (A330L), and a substitution of amino acid residue isoleucine at position 332 by a glutamic acid residue (I332E).
[0062] According to some embodiments, the polynucleotide sequence encodes the amino acid heavy chain or light chain of the above-mentioned antibody.
[0063] According to some embodiments, the encoded heavy chain is human IgG1.
[0064] According to some embodiments, the polynucleotide sequence encodes at least one amino acid chain of an antibody selected from a humanized antibody and a chimeric antibody.
[0065] According to some embodiments, the polynucleotide sequence encodes an antibody chain comprising the amino acid sequence set forth in any one of SEQ ID NO: 13, 14 or 15, or an analog or derivative thereof having at least 90% sequence identity to any of said amino acid sequences. Each possibility represents a separate embodiment of the invention.
[0066] According to some embodiments, the polynucleotide sequence encodes an antibody heavy chain amino acid sequence comprising a sequence selected from SEQ ID NO: 13 and SEQ ID NO: 15 or a variant thereof having at least 90% sequence identity thereto.
[0067] According to some embodiments, the polynucleotide encoding the antibody heavy chain is set forth in a sequence selected from the group consisting of SEQ ID NO: 22 and SEQ ID NO: 23, or a variant thereof having at least 80% sequence identity to the polynucleotide sequence.
[0068] According to some embodiments, the polynucleotide sequence encodes an antibody light chain amino acid sequence comprising the sequence set forth in SEQ ID NO: 14 or a variant thereof having at least 90% sequence identity thereto.
[0069] According to some embodiments, the polynucleotide sequence encoding the antibody light chain amino acid sequence comprises the sequence set forth in SEQ ID NO: 24 or a variant thereof having at least 80% sequence identity with the amino acid sequence.
[0070] According to yet another aspect of the present invention, there are provided vectors, plasmids and constructs carrying the polynucleotide sequences disclosed above.
[0071] According to some embodiments, the vector, plasmid or construct comprises a polynucleotide sequence encoding a heavy chain, wherein the polynucleotide sequence is selected from SEQ ID NO: 13 and SEQ ID NO: 15 or a variant thereof having at least 80% sequence identity thereto.
[0072] According to some embodiments, the vector, plasmid or construct comprises: a polynucleotide sequence encoding a heavy chain, the heavy chain being selected from SEQ ID NO: 13 and 15 or a variant thereof having at least 80% sequence identity; and a polynucleotide sequence encoding a light chain, the light chain being SEQ ID NO: 14 or a variant thereof having at least 80% sequence identity.
[0073] In yet another aspect, the present invention provides a host cell or a population or culture of host cells comprising at least one of the above polynucleotide sequences, vectors or constructs, wherein the cells are capable of producing at least one chain of the above antibody.
[0074] According to another aspect, the present invention also provides a composition comprising a plurality of antibody molecules that specifically bind to a glucocorticoid-induced TNFR-related (GITR) protein, wherein each antibody molecule comprises a variable region (Fab) and a modified human IgG1 constant region (Fc region), wherein the Fc region comprises an asparagine residue (N) at position 297, a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) G236A, and wherein approximately 65-100% of the antibody molecules in the composition comprise a mature core carbohydrate structure lacking fucose attached to the asparagine residue (N) at position 297 of the Fc region.
[0075] According to some embodiments, about 80-100% of the antibody molecules in the composition comprise a mature core carbohydrate structure lacking fucose attached to an asparagine residue (N) at position 297 of the Fc region.
[0076] According to other embodiments, about 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 80%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the antibody molecules in the composition comprise a mature core carbohydrate structure lacking fucose attached to an asparagine residue (N) at position 297 of the Fc region.
[0077] According to other embodiments, at least 70%, 75% or 80% of the IgG Fc regions of the antibody molecules are non-fucosylated. According to some specific embodiments, about 60-80% of the antibody molecules are defucosylated. Each option represents an independent embodiment of the present invention.
[0078] According to other embodiments, the present invention provides a composition comprising a plurality of afuco-G236A antibodies, the human IgG1 Fc region of which comprises less than 20%, less than 25% or less than 30% fucosylation. Each option represents a separate embodiment of the present invention.
[0079] According to some embodiments, the composition contains at least 50%, 60%, 70%, 80% or 90% less fucose moiety attached to N-297 of the human IgG1 Fc region of the afuco-G236A antibody molecule compared to the non-defucosylated antibody. Each option represents a separate embodiment of the present invention.
[0080] According to some embodiments, the GITR is human GITR (hGITR).
[0081] According to some embodiments, the Fab of each of the antibody molecules comprises a set of 6 CDR sequences, wherein the set is selected from:
[0082] i. A heavy chain (HC) CDR1 comprising the sequence GFSLSTSGMG (SEQ ID NO: 1), a HC CDR2 comprising the sequence IWWDDDK (SEQ ID NO: 2), a HC CDR3 comprising the sequence ARTRRYFPFAY (SEQ ID NO: 3), a light chain (LC) CDR1 comprising the sequence QNVGTN (SEQ ID NO: 4), a LC CDR2 comprising the sequence SAS or the sequence SAST (SEQ ID NO: 5), and a LC CDR3 comprising the sequence QQYNTDPLT (SEQ ID NO: 6);
[0083] ii. a HC CDR1 comprising the sequence SYGMH (SEQ ID NO: 7), a HC CDR2 comprising the sequence VIWYEGSNKYYADSVKG (SEQ ID NO: 8), a HC CDR3 comprising the sequence GGSMVRGDYYYGMDV (SEQ ID NO: 9), a LC CDR1 comprising the sequence RASQGISSALA (SEQ ID NO: 10), a LC CDR2 comprising the sequence DASSLES (SEQ ID NO: 11), and a LC CDR3 comprising the sequence QQFNSYPYT (SEQ ID NO: 12); and
[0084] iii. HC CDR1 comprising the sequence GYTFTRYW (SEQ ID NO: 25), HC CDR2 comprising the sequence IYPGDGDT (SEQ ID NO: 26), HC CDR3 comprising the sequence ARNPLTTATAWFVY (SEQ ID NO: 27), LC CDR1 comprising the sequence ENIYSN (SEQ ID NO: 28), LC CDR2 comprising the sequence AAT, and LC CDR3 comprising the sequence QHFWGPPWT (SEQ ID NO: 29).
[0085] According to some embodiments, each of the antibody molecules comprises the heavy chain sequence set forth in SEQ ID NO: 13, the light chain sequence set forth in SEQ ID NO: 14, or both.
[0086] According to some embodiments, the antibody molecule is a chimeric antibody or a humanized antibody.
[0087] According to some embodiments, the composition is in the form of a pharmaceutical composition further comprising at least one carrier, excipient or diluent.
[0088] According to another aspect of the present invention, a pharmaceutical composition is provided, which comprises at least one of the above-mentioned antibodies or antibody conjugates that specifically bind to GITR, and at least one carrier, excipient or diluent.
[0089] According to some embodiments, the pharmaceutical composition comprises an antibody as an active ingredient, the antibody comprising a variable region (Fab) that binds to GITR and a modified human IgG1 constant region (Fc), wherein the modified human IgG1 Fc region is selected from:
[0090] i. a human IgG1 Fc region comprising the substitution G236A and having a fucosylation content of 20-40% in all glycan structures (referred to herein as afuco-G236A); and
[0091] ii. a human IgG1 Fc region comprising the amino acid substitutions G236A, A330L and I332E (referred to herein as GAALIE).
[0092] According to some embodiments, the pharmaceutical composition comprises one or more antibodies as an active ingredient, the antibody being selected from: an isolated defucosylated antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), the Fc comprising an asparagine residue (N) at position 297, a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) G236A (referred to herein as afuco-G236A); A); and an antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), wherein the modified human IgG comprises the following amino acid substitutions: substitution of a glycine residue at position 236 with an alanine residue (G236A), substitution of an alanine residue at position 330 with a leucine residue (A330L), and substitution of an isoleucine residue at position 332 with a glutamic acid residue (I332E) (referred to herein as GAALIE).
[0093] According to some embodiments, the pharmaceutical composition comprises as an active ingredient at least one antibody that specifically binds to GITR or a conjugate thereof, the antibody comprising a modified IgG1 Fc region comprising a substitution of amino acid residue glycine (G) at position 236 by alanine (A), and having a fucosylation content of up to 40% in all glycan structures.
[0094] According to some embodiments, the pharmaceutical composition comprises at least one antibody that specifically binds to GITR or a conjugate thereof as an active ingredient, the antibody comprising a modified IgG1 Fc region comprising a substitution of the amino acid residue glycine at position 236 by an alanine residue (G236A), a substitution of the amino acid residue alanine at position 330 by a leucine residue (A330L), and a substitution of the amino acid residue isoleucine at position 332 by a glutamic acid residue (I332E).
[0095] According to some embodiments, the pharmaceutical composition comprises an antibody comprising a set of 6 CDRs, wherein: the heavy chain CDR1 comprises SEQ ID NO: 1; the heavy chain CDR2 comprises SEQ ID NO: 2; the heavy chain CDR3 comprises SEQ ID NO: 3; the light chain CDR1 comprises SEQ ID NO: 4; the light chain CDR2 comprises SEQ ID NO: 5; and the light chain CDR3 comprises SEQ ID NO: 6.
[0096] According to some embodiments, the pharmaceutical composition comprises an antibody comprising a set of 6 CDRs, wherein: the heavy chain CDR1 comprises SEQ ID NO: 7; the heavy chain CDR2 comprises SEQ ID NO: 8; the heavy chain CDR3 comprises SEQ ID NO: 9; the light chain CDR1 comprises SEQ ID NO: 10; the light chain CDR2 comprises SEQ ID NO: 11; and the light chain CDR3 comprises SEQ ID NO: 12.
[0097] According to a specific embodiment, the pharmaceutical composition comprises an antibody comprising a heavy chain having a sequence selected from SEQ ID NOs: 13 and 15 and a light chain having a sequence of SEQ ID NO: 14. Each possibility represents a separate embodiment of the invention.
[0098] The pharmaceutical composition of the present invention can be formulated to be administered by any means suitable for antibody administration. According to some embodiments, the pharmaceutical composition is formulated for intravenous (iv) administration. In some embodiments, the pharmaceutical composition is formulated for administration by injection or infusion.
[0099] Also provided is a pharmaceutical composition comprising at least one of the above antibodies or antibody conjugates for enhancing the immune co-stimulatory activity of hGITR.
[0100] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to activate dendritic cells, activate phagocytosis and enhance the production of pro-inflammatory cytokines.
[0101] According to some embodiments, the pharmaceutical composition is used to treat cancer or tumor.
[0102] According to some embodiments, the tumor is a solid tumor. According to other embodiments, the cancer is a hematological cancer.
[0103] According to some embodiments, the cancer is a metastatic cancer.
[0104] According to some specific embodiments, the solid cancer is selected from non-small cell lung cancer (NSCLC), renal cell carcinoma, melanoma, glioblastoma, colorectal cancer, breast cancer and ovarian cancer.
[0105] According to some embodiments, the treatment of cancer or tumor comprises administering or performing at least one additional anti-cancer therapy. According to certain embodiments, the additional anti-cancer therapy is selected from surgery, chemotherapy, radiotherapy, immunotherapy and hormone therapy.
[0106] According to some embodiments, the treatment of cancer or tumor comprises administering the anti-hGITR antibody or conjugate thereof and an additional anti-cancer agent. According to some embodiments, the additional anti-cancer agent is selected from immunomodulators, agents that bind to tumor antigens or receptors overexpressed on tumor cells, and chemotherapeutic agents.
[0107] According to some embodiments, treatment of cancer or tumors includes delaying, slowing or preventing tumor growth or recurrence.
[0108] According to some embodiments, treatment of cancer or tumor results in preventing or reducing the formation, growth or spread of metastases in said subject.
[0109] According to some embodiments, treatment of cancer or tumor results in enhanced anti-tumor effects.
[0110] According to some embodiments, treatment of cancer or tumors results in the induction of long-term anti-tumor immunity.
[0111] According to some embodiments, treatment of cancer or tumor results in modulation of the tumor microenvironment by targeting hGITR and through Fc region-mediated activation of FcγRIIA and / or FcγRIIIA of effector cells.
[0112] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to enhance the anti-tumor effect by activating effector cells via hGITR and via FcγRIIA and / or FcγRIIIA.
[0113] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to induce long-term anti-tumor immunity.
[0114] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to deplete or inhibit regulatory T cells (Treg).
[0115] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to activate dendritic cells.
[0116] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to modulate the tumor microenvironment by targeting GITR and mediated FcγRIIA and / or FcγRIIIA activation of effector cells through the Fc region.
[0117] According to some embodiments, the pharmaceutical composition comprising at least one of the above-mentioned Fc-modified antibodies against hGITR is used to delay, slow down or prevent tumor growth and metastasis formation or spread.
[0118] According to yet another aspect and some embodiments, the present invention provides a method for enhancing hGITR activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-GITR antibody or a conjugate thereof as defined herein, or a pharmaceutical composition comprising the same, wherein the anti-GITR antibody has agonist activity.
[0119] According to yet another aspect, the present invention provides a method for treating cancer or tumors, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an anti-hGITR antibody with a modified Fc region as described herein or a conjugate thereof.
[0120] According to some embodiments, the method of treating cancer or tumor in a subject in need of treatment comprises administering or performing at least one additional anti-cancer therapy. According to certain embodiments, the additional anti-cancer therapy is selected from surgery, chemotherapy, radiotherapy, immunotherapy and hormone therapy.
[0121] According to some embodiments, the method of treating cancer or tumor comprises administering the anti-hGITR antibody or its conjugate and an additional anti-cancer agent. According to some embodiments, the additional anti-cancer agent is selected from immunomodulators, agents that bind to tumor antigens or receptors overexpressed on tumor cells, and chemotherapeutic agents.
[0122] According to some embodiments, the immunomodulator is a checkpoint inhibitor.
[0123] According to some embodiments, the method of treating cancer or a tumor in a subject in need thereof results in preventing or reducing formation, growth, or recurrence in the subject.
[0124] According to some embodiments, the method of treating cancer or tumors comprises delaying, slowing or preventing metastasis formation or spread.
[0125] According to some embodiments, the method of treating cancer or tumor comprises enhancing the anti-tumor effect.
[0126] According to some embodiments, the method of treating cancer or tumors comprises inducing long-term anti-tumor immunity.
[0127] According to some embodiments, the method of treating cancer or tumors comprises modulating the tumor microenvironment by targeting hGITR and through Fc region-mediated activation of FcγRIIA and / or FcγRIIIA of effector cells.
[0128] According to some embodiments, the present invention provides a method for activating dendritic cells, activating phagocytosis, and enhancing the production of pro-inflammatory cytokines, the method comprising administering at least one of the above-mentioned Fc-modified antibodies against hGITR.
[0129] According to some embodiments, the present invention provides a method for preventing, delaying, depleting or inhibiting Tregs, the method comprising administering at least one of the above-mentioned Fc-modified antibodies against hGITR.
[0130] According to the present invention, there is also provided a kit, which comprises the above-mentioned antibody, antibody conjugate or composition, which is packaged in a packaging material and marked in a printed manner in or on the packaging material.
[0131] Also within the scope of the invention are methods of producing and purifying the anti-GITR antibodies or antibody conjugates of the invention.Any method known in the art for producing, isolating and purifying recombinant antibodies may be used.
[0132] According to some embodiments, the antibodies are produced by transiently transfecting a plasmid comprising polynucleotide sequences encoding the heavy and light chain pairs into cells.
[0133] According to some embodiments, the method of producing an Fc-modified antibody against GITR comprises:
[0134] (i) transfecting a vector, plasmid or construct comprising a polynucleotide sequence encoding a heavy chain and a light chain pair into a cell;
[0135] (ii) culturing a cell comprising at least one polynucleotide encoding a heavy chain or a light chain of an antibody under conditions that allow expression of said heavy chain and / or light chain; and
[0136] (iii) recovering the chains from the cells.
[0137] According to other embodiments, the antibody is assembled in the cell, secreted into the cell culture supernatant, and then recovered, isolated and purified.
[0138] According to some embodiments, the isolation and purification comprises one or more of the following steps: collecting the culture medium, centrifugation to pellet the cells and any particulate matter, filtration, purification using chromatography, and buffer exchange.
[0139] According to some embodiments, the chromatography is Protein G chromatography.
[0140] According to specific embodiments, the humanized antibody or antibody fragment is purified to a purity level of at least 95%, 96%, 97%, 98%, 99% or even higher (less than 5% host cell contaminants w / w or w / v).
[0141] The Fc-defucosylated antibodies of the present invention may be produced using any method known in the art for producing defucosylated antibodies.
[0142] According to some embodiments, the defucosylation of the antibody is performed without modifying the amino acid glycosylation site (eg, without substituting or deleting the asparagine (N) amino acid residue at position 297 of the Fc).
[0143] According to some embodiments, defucosylation of the antibody is performed post-translation during the transfection step.
[0144] According to some embodiments, the method for producing a defucosylated Fc-modified antibody comprises adding 50-500 μM 2-deoxy-2-fluoro-L-fucose to the transfection medium. BRIEF DESCRIPTION OF THE DRAWINGS
[0145] Figure 1A and 1B is a schematic diagram of the FcγR pathway of agonistic anti-GITR antibodies, showing the activation of the FcγR pathway ( Figure 1A ) and binding of FcγR as a scaffold for antibody cross-linking ( Figure 1B ).
[0146] Figure 2 Schematic diagram of an exemplary cloning strategy for producing some antibodies of the present invention. Human IgG1 was cloned and introduced into a mammalian expression vector. The labeled bands of the heavy chain (HC) and light chain (LC) constant regions of hIgG1 were extracted from 1% agarose gel and connected to the heavy chain and light chain variable regions (VH and VL) of anti-mouse GITR (mGITR) for expression and production of Fc region variant antibodies.
[0147] Figure 3A-3Bis a non-reducing chimeric rat anti-mGITR hIgG1 Fc region variant based on the rat anti-mGITR antibody DTA-1 ( Figure 3A ) and restore ( Figure 3B )SDS-PAGE. In non-reducing SDS-PAGE, the disulfide bonds between the heavy and light chains are intact, so only one band appears at the size of the intact antibody ( Figure 3A ), while in reducing SDS-PAGE ( Figure 3B ) Two distinct bands appeared: one representing the heavy chain ~50 kDa and the other representing the light chain ~25 kDa. Lane 1 - molecular weight marker, lane 2 - anti-mGITR V11, lane 3 - defucosylated anti-mGITR, lane 4 - N279A, lane 5 - GAALIE, lane 6 - GASDALIE, lane 7 - G236A, lane 8 - anti-mGITR IgG1.
[0148] Figure 4 is a graphical representation showing similar binding affinities of several chimeric anti-mGITR hIgG1-Fc modified variants (containing Fabs of anti-mGITR DTA-1) to plate-bound mouse GITR. ELISA OD450 values are plotted against increasing concentrations of the antibodies tested. Data are expressed as mean ± SEM.
[0149] Figures 5A-5D is a graph demonstrating the differential binding affinities of chimeric anti-mGITR hIgG1 Fc region variants (containing the Fab of DTA-1) to the indicated hFcγRs; hFcγRIa ( Figure 5A )、hFcγRIIA( Figure 5B )、hFcγRIIB( Figure 5C ) and hFcγRIIIA( Figure 5D ). Data are expressed as mean ± SEM.
[0150] Figure 6 Depicted are the results of pharmacokinetic assays of several chimeric anti-mGITR IgG1 Fc region variants, including the Fab of DTA-1, measured as the in vivo half-life of the antibody. Data are presented as mean ± SEM. n=3.
[0151] Figures 7A-7H Differential anti-tumor activity of chimeric anti-mGITR hIgG Fc region variants was shown. FcγR humanized (hFcγR) mice were inoculated with MC38 cells and treated with chimeric human Fc region variants of DTA-1 antibody. Tumor progression and overall survival of mice were tracked. Untreated mice (n=10) ( Fig. 7A ), IgG1 treatment (n=8) ( Figure 7B), IgG1-N297A treatment (n=10) ( Figure 7C ), IgG1-V11 treatment (n=10) ( Fig.7D ), IgG1-G236A treatment (n=9) ( Fig. 7E ), Afuco-IgG1 treatment (n=10) ( Figure 7F Unpaired two-tailed t-test was used to compare the Fc region variants with the IgG1-N297A group ( Figure 7G ), comparing the survival probability between Fc region variants ( Figure 7H ). Asterisks indicate statistical comparison with IgG1-N297A. Data are presented as mean ± SEM.
[0152] Figures 8A-8B Figure 1 is a graphic representation of the protection afforded by anti-GITR treatment in a tumor rechallenge model as an indication of long-term immunity. Naive mice and MC38-bearing hFcγR mice treated with anti-mGITR Fc region variants (which fully responded to previous treatment and became tumor-free; IgG1 (n=4), IgG1-N297A (n=1), IgG1-G236A (n=6), Afuco-IgG1 (n=7)) were rechallenged and tumor growth was tracked ( Fig. 8A ) and the survival probability ( Figure 8B ). Asterisks indicate statistical comparisons with naive mice. Data are presented as mean ± SEM.
[0153] Figures 9A-9F Long-term protective effects of anti-mGITR mAbs against tumor re-emergence and memory responses are depicted. MC38-bearing hFcγR mice treated with anti-GITR Fc region variants, which fully responded to previous treatment and became tumor-free, were compared to the same type of tumor-free mice injected with antibody-depleted CD4 and CD8 cells. For each Fc region variant treatment, tumor growth in T-cell-depleted mice was compared to non-T-cell-depleted mice: untreated (n=6, Fig. 9A ), IgG1-G236A (T cell depletion n=4, non-T cell depletion n=2, Fig. 9B ), Afuco-IgG1 (T cell depletion n=3, non-T cell depletion n=2, Fig. 9C ), and Afuco-IgG1-G236A (T cell depletion n=2, non-T cell depletion n=4, Fig.9D ). Effect of tumor growth over time ( Fig.9E ) and the survival probability ( Fig.9F ). Asterisks indicate statistical comparisons between T cell-depleted mice and non-T cell-depleted mice treated with the same Fc region variant. Data are expressed as mean ± SEM.
[0154] Figures 10A-10C The chimeric Fc region modified anti-mGITR (DTA-1Fab) variants were compared with hFcγRIIA ( Fig. 10A )、hFcγRIIIA( Fig. 10B ) and hFcγRIIB( Fig. 10C ) Graphical representation of binding. Data are presented as mean ± SEM.
[0155] Figures 11A-11F Figure 1 is a graphic representation of the enhanced FcγRIIA and FcγRIIIA activity mediated by chimeric anti-mouse GITR antibodies with Fc region modifications. Humanized FcγR mice were inoculated with MC38 cells and once tumors reached 115 mm 3 The mean volume of untreated mice ( Fig.11A ), IgG1-G236A( Fig. 11B ), Afuco-IgG1( Fig. 11C ), Afuco-IgG1-G236A( Fig.11D ), mean tumor growth was compared for all Fc region variants, and unpaired two-tailed t-test was used to compare the Afuco-IgG1-G260A and Afuco-IG1 groups ( Fig.11E ) and the survival probability ( Fig.11F ). Data are expressed as mean ± SEM.
[0156] Figures 12A-12F The chimeric anti-mGITR hIgG Fc region variants demonstrated enhanced antitumor activity. Humanized FcγR mice were inoculated with MC38 cells and once tumors reached 115 mm 3 The average volume of , was treated with the indicated chimeric antibody variants (based on DTA-1). Mice were followed for tumor progression: Untreated mice ( Fig. 12A ), IgG1( Fig. 12B ), IgG1-N297A( Fig. 12C ), Afuco-IgG1-G236A( Fig.12D ), the mean tumor growth of all Fc region variants was compared, and the Afuco-IgG1-G236A and IgG1 groups ( Fig.12E ) and the survival probability ( Fig.12F ). Data are expressed as mean ± SEM.
[0157] Figures 13A-13FThe frequency of T cells in the TME at 1, 4 and 8 days after the start of anti-GITR Fc region variant treatment is shown. Humanized FcγR mice with refractory MC38 tumors were treated with chimeric anti-mGITR Fc region variants IgG1-N297A (NA), Afuco-IgG1-G236A (GA-aFuc) and IgG1. Mice were sacrificed and tumors were harvested at three time points after treatment, namely 1 day, 4 days (2 mAb administrations in total) and 8 days (3 mAb administrations in total), and untreated mice were used as controls. Figures 13A-13C , Flow cytometric analysis of Treg frequency detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+: 1 day after the start of treatment ( Fig.13A ), 4 days after the start of treatment ( Fig. 13B ) and 8 days after the start of treatment ( Fig. 13C ). Figures 13D-13F , Flow cytometric analysis of CD8+ frequency detected by CD45+CD3+CD11b-CD8+CD4-: 1 day after the start of treatment ( Fig.13D ), 4 days after the start of treatment ( Fig.13E ) and 8 days after the start of treatment ( Fig.13F ). Figures 13G-13I , CD8 / Treg ratio in mouse TME: 1 day after treatment start ( Figure 13G ), 4 days after the start of treatment ( Fig.13H ) and 8 days after the start of treatment ( Fig.13I ).
[0158] Figures 14A-14G Flow cytometric analysis of DC activation status in the TME and dLN of humanized FcγR mice with refractory MC38 tumors treated with Afuco-IgG1-G236A (GA-aFuc), IgG1-Fc silencing N297A (NA), and IgG1 is depicted. TME and dLN were harvested 4 and 8 days after the start of treatment, and untreated mice were used as controls (untreated). DCs were detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+; activated CD80 DCs were detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+CD80+CD86-, and activated CD86 DCs were detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+CD80-CD86+. Fig.14A Shown are the percentages of DCs in the TME 4 days after the start of treatment. Fig. 14B Shown are the geometric mean fluorescence intensity (gMFI) of activated CD80 DCs in the TME 4 days after the start of treatment. Fig. 14CShown are the gMFI of activated CD86 DCs in the TME 4 days after the start of treatment. Fig.14D Shown are the percentages of DCs in dLN 4 days after the start of treatment. Fig.14E Shown are the geometric mean fluorescence intensity (gMFI) of activated CD80 DCs in dLN 4 days after the start of treatment. Fig.14F Shown are the gMFI of activated CD86 DCs in dLN 4 days after the start of treatment. Figure 14G Shown are the percentages of DCs in the TME 8 days after the start of treatment.
[0159] Figures 15A-15C Figure 2 is a graphic representation of the differential binding affinities of humanized anti-hGITR (TRX518) IgG1 Fc region variants to hGITR and the indicated hFcγRs. Comparative ELISA was used to evaluate the binding affinity of the anti-human IgG1 Fc region variants to hGITR ( Fig.15A )、Human FcγRIIA( Fig. 15B ) and FcγRIIIA( Fig. 15C ) binding affinity. OD450 values were plotted against increasing concentrations of the test antibody to assess binding of plate-bound proteins. Data are presented as mean ± SEM.
[0160] Fig.16 is a graphical representation of the effect of T cell frequency in the blood after treatment with anti-hGITR antibodies. Humanized FcγR and hGITR mice inoculated with MC38 tumors were treated with humanized Fc region modified variants of anti-hGITR antibodies, IgG1-N297A and Afuco-IgG1-G236A, both containing the Fab of TRX518. After one mAb administration, blood was collected at the following time points: 2 days before treatment, 2, 22 and 96 hours after treatment. Data are expressed as mean ± SEM, and ordinary one-way ANOVA was performed using Tukey's multiple comparison statistical test. For all groups, n = 5.
[0161] Figures 17A-17C Figure 2 shows the frequency of T cells in the TME after anti-hGITR treatment. Humanized FcγR / GITR mice with refractory MC38 tumors were treated with anti-hGITR Fc region variants IgG1-N297A (TRX518) and Afuco-IgG1-G236A. Tumors were harvested 4 days after the start of treatment (2 mAb administrations in total), single cell suspensions were prepared, and CD4FoxP3-( Fig.17A )、CD8( Fig. 17B ) and Treg( Fig. 17C ) Regulation of the immune compartment of the TME. Data are expressed as mean ± SEM and subjected to Kruskal-Wallis statistical test.
[0162] Fig.18A Figure 1 is a timeline of in vivo NK depletion testing, from inoculation of refractory MC38 tumor cells into mice to day 4 from initiation of anti-mGITR hIgG1 Fc region variant treatment (at which time blood was drawn and tumors harvested), including the schedule for NK depletion by αNK1.1. Evaluation of NK cells required Treg depletion by Afuco-IgG1-G236A.
[0163] Figures 18B-18C was initiated from Afuco-IgG1-G236A or IgG1-Fc silencing N297A (NA) treatment and on day 0 after NK cell depletion ( Fig.18B ) and Day 4 ( Fig.18C ) Flow cytometry of NK cells in mouse blood samples. NK cells were detected by CD45+CD3-NKp46+, and blood from mice treated with PBS alone was used as a negative control. Figures 18D-18F Depicted are the cell counts per mg of tumor: NK cells ( Fig.18D ), Treg cells (detection of CD45+CD3+CD11b-CD8-CD4+FoxP3+, Fig.18E ) and CD8+ cells (detection of CD45+CD3+CD11b-CD8+CD4-, Fig.18F ).
[0164] Figures 19A-19C Depicted is an ELISA assay measuring binding of novel anti-mGITR bispecific variants to different hFcγRs compared to the monospecific Afuco-IgG1-G236A (DTA1 GA-aFuc, circles) as a control. Non-agonistic bispecific antibodies were generated based on the following Fc scaffolds: (i) Afuco-IgG1-G236A and Synangsis antibodies (GITR / Afuco-IgG1-G236ASyn, DTA1 / Syn GA-aFuc, triangles) and (ii) IgG1-N297A and Synangsis (GITR / NA SynDTA1 / NA Syn), inverted triangles). Binding of Ab to FcγRIIA ( Fig.19A )、FcγRIIB( Fig.19B ) and FcγRIIIA( Fig.19C ) combination. Fig.19D , HPLC characterization of the bispecific anti-GITR GITR / Afuco-IgG1-G236A Synagis non-agonistic antibody digested with trypsin.
[0165] Fig. 20ADepicted is the binding capacity of a novel non-agonist bispecific anti-mGITR mAb with N297A substitution in the Fc (denoted as "mGITR / NA Synagis") (DTA-1 / SynagsisNA, squares) compared to monospecific mIgG1-N297A (filled circles). A non-GITR binding antibody with N297A substitution in the Fc region was used as an isotype control (isotype control NA, triangles). The binding capacity was determined by ELISA and the OD450 values were plotted against increasing concentrations of the indicated antibodies.
[0166] Fig. 20B Depicted are IL-2 secretion from isolated T cells from wild-type (WT) mice (activated with anti-CD3 antibodies) after incubation with increasing concentrations of anti-mGITR / NA Synagis (DTA-1 / Synagsis NA, squares), monospecific mIgG1-N297A (DTA-1 NA, solid circles), or a non-GITR binding antibody with a N297A substitution in the Fc region (isotype control NA) (triangles) as an isotype control. ELISA was performed on supernatants of activated T cells incubated with Ab.
[0167] Fig.21 Flow cytometric analysis of the percentage of Tregs in the TME of hFcγR mice with MC38 tumors after different treatments. Mice were treated (IP) with 100 μg, 200 μg or 400 μg of a humanized GA-aFuc Fc region variant (GITR / syn-GA-aFuc) of a non-agonistic bispecific Ab or 100 μg of mouse anti-DTA-1 (anti-GITR) GA-aFuc Ab. Tumors from untreated mice as well as negative controls were analyzed.
[0168] Figures 22A-22C Depicted are tumor volumes (mm) of hFcγR mice bearing MC38 tumors after treatment with 100 μg GA-aFuc Ab (solid triangles) or 200 μg non-agonistic GITR / syn GA-aFuc Ab (open triangles). 3 ) progression. Untreated mice served as controls (solid circles). Fig.22A Tumor volume measurements at day 20 are depicted. Fig. 22B Tumor volumes of mice in all groups at day 13 after the start of treatment are depicted. Fig. 22C Depicted are the tumor volumes of mice in the GA-aFuc Ab and GITR / syn GA-aFuc Ab test groups at day 15 after the start of treatment.
[0169] Figures 23A-23BFlow cytometric analysis of the percentage of Tregs and dendritic cells (DCs) in the TME of hFcγR mice bearing MC38 tumors after treatment with 200μg GITR / syn GA-aFuc (triangles) and 100μg GA-aFuc (squares). Tumors from untreated mice and negative controls (circles) were analyzed. Tregs were detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+, and DCs were detected by CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+.
[0170] Figures 23C-23D Flow cytometric analysis of DC activation by measuring the percentage of DC expressing CD80+ or CD86+, respectively. Tumors from untreated mice and negative controls were analyzed. DC were detected by CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+, CD80+DC were detected by adding anti-CD80 antibody, and CD86+DC were detected by adding anti-CD86 antibody.
[0171] Fig.24A Depicted is 17-day monitoring of tumor volume progression in wild-type WT C57BL / 6J mice bearing MC38 tumors after treatment with 100 μg DTA-1mIgG2a (squares) or 100 μg anti-GITR-mIgG2a N279A Ab (DTA-1mIgG2a NA, open triangles). Untreated mice were used as controls (closed circles). Figures 24B-24E , Flow cytometric analysis of modulation in immune compartments in the TME of WT mice bearing MC38 tumors treated with 100 μg DTA-1mIgG2aAb (squares) and 100 μg DTA-1mIgG2a NA (triangles) or untreated mice used as controls (circles). Tumors were harvested 4 days after treatment and analyzed. Fig. 24B , Treg counts / mg tumor detected using anti-FoxP3 antibody in all tested groups. Fig.24C , The percentage of DCs to total lymphocytes in all test groups (detected using anti-CD11c antibody / anti-CD45 antibody). Fig.24D , ΔgMFI of CD80+ activated DCs in all tested groups. Fig.24E , ΔgMFI of CD86+ activated DCs in all tested groups.
[0172] Fig.25 Figure 3 is a graph of BATF3 cells with MC38 tumors treated with 100 μg of DTA-1mIgG2a (squares) Ab and 100 μg of DTA-1mIgG2a-NA Ab (triangles).- / - Tumor volume (mm) at day 13 in mice treated with PD-1 or untreated mice used as controls (circles). 3 ) graphical representation of the measured values.
[0173] Figures 26A-26B Tumor volume (mm) in XCR1-iDTR and ZBTB46-iDTR NC38 tumor-bearing mice treated with 100 μg DTA-1mIgG2a Ab, 20 ng / gr body weight of diphtheria toxin (DT), or a combination of 100 μg DTA-1mIgG2a Ab and 20 ng / gr body weight of DT, respectively. 3 ) Graphical representation of the progression. Untreated mice were used as controls. DT was injected every other day at 20 ng / g to deplete DCs. Fig.26A is the 13-day tumor volume (mm) in XCR1-iDTR mice 3 ) progress, the mouse is a DT-mediated inducible cDC1 cell depletion model. Fig.26B is the 20-day tumor volume (mm) in ZBTB46-iDTR mice 3 ) progress, the mouse is a DT-mediated inducible cDC1 and cDC2 cell depletion model.
[0174] Figures 27A-27B Percentage of Tregs in the TME and percentage of DCs in dLN from mice treated with 100 μg mouse anti-GITR Ab, 100 μg anti-CD25 Ab or untreated mice, respectively. Organs were harvested 4 days after treatment.
[0175] Figures 27C-27D Depicted are the ΔgMFI of CD80+ and CD86+ activated DCs in dLNs from mice treated with 100 μg mouse anti-GITR Ab, 100 μg anti-CD25 Ab, or untreated mice, respectively. dLNs were harvested 4 days after treatment. Fig.27C The ΔgMFI of CD80+ activated DCs is depicted. Fig.27D The ΔgMFI of CD86+ activated DCs is depicted.
[0176] Figures 28A-28C Depicts the progression of tumor volume in mice bearing MC38 tumors treated three times with 100 μg / mouse of IgG1-N297A (N297A) or IgG1-GAALIE (GAALIE). Untreated mice were used as controls. Each line represents one animal.
[0177] Fig.28DIs a graphic representation of the mean tumor volume progression for each treatment group IgG1-N297A (N297A, n=8), IgG1-GAALIE (GAALIE, n=9), control untreated mice (untreated, n=8). An unpaired two-tailed t-test was used to compare the IgG1-N297A and IgG1-GAALIE groups. Data are expressed as mean ± SEM.
[0178] Any embodiment disclosed above can be optionally combined with the subject matter of one or any combination of another embodiment disclosed herein. From the detailed description given below, further embodiments of the present invention and the full scope of application will become apparent. However, it should be understood that the detailed description and specific examples, although indicating preferred embodiments of the present invention, are given only by way of illustration, because for those skilled in the art, from the detailed description, various changes and modifications within the spirit and scope of the present invention will become apparent. DETAILED DESCRIPTION
[0179] The present invention provides antibodies specific for human glucocorticoid-induced TNFR-related (hGITR, also known as CD357 or TNFRSF18) proteins, which contain modified human IgG1 Fc, which exhibits an enhanced binding ratio with activating FcγRIIA and / or FcγRIIIA relative to binding with FcγRIIB, enhancing control of tumor growth and overall survival. The Fc-modified anti-hGITR antibodies of the present invention are designed by combining two strategies-glycoengineering, i.e., changing the content of the sugar moiety (e.g., defucosylation), and protein engineering by replacing one or more amino acids (e.g., G236A). In the process of developing the anti-GITR antibodies of the present invention, preliminary experiments were conducted in human FcγR mice to test chimeric anti-mouse GITR antibodies containing human IgG1 Fc regions and variants thereof. After showing promising anti-tumor activity, anti-hGITR antibodies containing modified hIgG1 Fc regions were produced and tested in human FcγR-human GITR mouse models.
[0180] Compared to reduced or unchanged binding affinity to FcγRIIB, the antibodies of the present invention have enhanced affinity for FcγRIIA and / or FcγRIIIA, resulting in a significantly improved activation / inhibition ratio. This ratio is directly related to the ability of the antibody to stimulate the immune system by activating dendritic cells, phagocytosis, and producing proinflammatory cytokines, which in turn trigger anti-tumor effects and long-term anti-tumor immunity. Surprisingly, the Fc-modified antibodies of the present invention enhance anti-tumor immune activity without the need to activate the GITR receptor.
[0181] Without wishing to be bound by any theory of mechanism of action, it is suggested that the reduced binding of the Fc-modified IgG1 of the anti-hGITR antibodies of the invention to FcγRIIB relative to binding to activating receptors impairs the cross-linking activity of the antibody. TNFR family members are known to play a role in enhancing agonistic activity through antibody cross-linking mechanisms binding to FcγRIIB. Surprisingly, even in the absence of such cross-linking, the Fc-modified anti-hGITR antibodies of the invention showed a significant enhancement of anti-tumor activity.
[0182] Compared to antibodies comprising substantially the same antigen binding site (e.g., antibodies referred to herein as "IgG1," "IgG1-N297A," or "V11"), antibodies of the invention (e.g., antibodies referred to herein as "defucosylated IgG1-G236A," or "afuco-G236A," and "GAALIE") exhibit enhanced binding to FcγRIIA and FcγRIIIA activating receptors relative to binding to inhibitory receptor FcγRIIB. The "V11" Fc variant that exhibits high affinity for FcγRIIB is unable to elicit anti-tumor effects and long-term anti-tumor immunity.
[0183] The anti-hGITR antibodies of the present invention reduce the frequency of Tregs in the TME through an Fc-mediated depletion mechanism. Using the Fc-modified Afuco-G236A antibody, CD4 Treg reduction occurs at an early time point. Anti-hGITR antibody-mediated Treg depletion is FcγR-dependent. The Afuco-G236A anti-hGITR antibody of the present invention shows FcγR-mediated Treg depletion, while the antibody TRX518, which is currently in clinical trials, is an Fc region-silent antibody that does not mediate Treg depletion. In addition, among all the Fc region variants tested, the Afuco-G236A Fc-modified variant of the present invention shows the highest increase in the density of both DC activation markers CD80 and CD86 in tumors and draining lymph nodes (dLN). IgG1 Fc-silent N297A did not show an increase in CD80 or CD86 markers.
[0184] Again unexpectedly, the Fc-modified antibodies of the present invention, despite predominantly binding to activating receptors, do not enhance cross-linking and exhibit improved anti-cancer activity compared to similar antibodies with different Fc scaffolds.
[0185] definition
[0186] The term "glucocorticoid-induced TNFR family-related receptor" (abbreviated herein as "GITR"), also known as TNF receptor superfamily 18 (TNFRSF18), AITR, CD357, ENERGEN or GITR-D, as used herein, refers to a member of the tumor necrosis factor / nerve growth factor receptor family. The human member is a type I transmembrane protein characterized by three cysteine pseudo-repeats in the extracellular domain (Nocentini, G. et al., (1997), Proc. Natl. Acad. Sci., USA 94: 6216-622). The Fc-modified antibodies of the present invention can be directed against any human GITR protein variant expressed on human cancer cells and / or human immune cells. Non-limiting examples of human protein variants include accession number NM_004195.3, a 241 amino acid protein with accession number NP_004186.1 and GI: 4759246, a 255 amino acid protein with accession number N_683699.1 and GI: 23238194, and a 234 amino acid protein with accession number NP_683700.1 and GI: 22338197. Non-limiting exemplary mouse GITR protein variants are accession number NM_021985.3, a 132 amino acid protein with accession number NP_068820.1 and NM_009400.3, and a 228 amino acid protein with accession number NP_033426.1.
[0187] Antibodies or immunoglobulins contain two heavy chains linked together by disulfide bonds and two light chains, each light chain being connected to a corresponding heavy chain by disulfide bonds in a "Y"-shaped structure. Each heavy chain has a variable domain (V H ), followed by multiple constant domains (C H Each light chain has a variable domain (V L ), with a constant domain (C L ), the variable domain of the light chain is aligned with the variable domain of the heavy chain, and the constant domain of the light chain is aligned with the first constant domain (CH1) of the heavy chain. Each pair of variable domains of the light chain and the heavy chain forms an antigen binding site (Fab). The domains on the light and heavy chains have the same overall structure, and each domain includes four framework regions, whose sequences are relatively conservative, connected by three hypervariable domains called complementarity determining regions (CDRs). These domains contribute to the specificity and affinity of the antigen binding site.
[0188] "Framework region" and "FR" are known in the art and refer to the non-CDR portions of the heavy and light chain variable regions. Generally, there are four FRs (FR-H1, FR-H2, FR-H3, and FR-H4) in each full-length heavy chain variable region, and four FRs (FR-L1, FR-L2, FR-L3, and FR-L4) in each full-length light chain variable region. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described in Kabat et al., (1991), Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme); Al-Lazikani et al., (1997), JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding sitetopography", J. Mol. Biol.262, 732-745 ("Contact" numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", Dev Comp Immunol, 2003 Jan, 27(1): 55-77 ("IMGT" numbering scheme); Honegger A and Plückthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J Mol Biol, 2001 Jun 8; 309(3): 657-70 ("Aho" numbering scheme); Whitelegg NR and Rees AR, "WAM: an improved algorithm for modelling antibodies on the Internet" WEB), Protein Eng. 2000 Dec; 13(12): 819-24 ("AbM" numbering scheme).
[0189] Several methods are known in the art for determining the CDR sequences of given antibody molecules, but there is no standard clear method. Determination of the CDR sequences from antibody heavy chain and light chain variable regions can be carried out according to any method known in the art, including but not limited to Kabat, Chothia and IMGT methods. According to a group of selected CDRs of the present invention, the sequences identified by more than one method can be included, i.e., for example, some CDR sequences can be determined using Kabat, and others are determined using IMGT. According to some embodiments, the CDR sequences of antibody variable regions are determined using Kabat and / or Chothia methods. In certain embodiments, the CDR of antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM or a combination thereof. In some embodiments, CDR is defined using Kabat.
[0190] Changes (e.g., substitutions) can be made in the CDRs, for example, to improve antibody affinity. Such changes can be made in codons encoding CDRs with a high mutation rate during somatic maturation (e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)), and the resulting variants can be tested for binding affinity. Affinity maturation (e.g., using error-prone PCR, chain shuffling, CDR randomization, or site / oligonucleotide directed mutation) can be used to improve antibody affinity (e.g., Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (2001)). The CDR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling (e.g., Cunningham and Wells, Science, 244: 1081-1085 (1989)). Specifically, CDR-H3 and CDR-L3 are often targeted.
[0191] Also included within the scope of the present invention are chimeric antibodies, human and humanized antibodies, recombinant and engineered antibodies and conjugates thereof. In addition, DNA encoding the variable regions of antibodies can be inserted into DNA encoding other antibodies to produce chimeric antibodies.
[0192] Specifically, antibodies herein include "chimeric" antibodies. Chimeric antibodies are molecules in which different parts are derived from different animal species, such as molecules with variable regions derived from murine mAbs and human immunoglobulin constant regions. Antibodies with variable region framework residues substantially from human antibodies and complementary determining regions substantially from mouse antibodies are also referred to as humanized antibodies. Chimeric antibodies are mainly used to reduce immunogenicity in applications and increase yield in production, such as when murine mAbs have higher yields from hybridomas, but in humans, human / murine chimeric mAbs are used. Chimeric antibodies and methods for their preparation are known in the art (e.g., PCT patent applications WO 86 / 01533, WO 97 / 02671, WO 90 / 07861, WO 92 / 22653 and U.S. Patents 5,693,762, 5,693,761, 5,585,089, 5,530,101 and 5,225,539).
[0193] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies containing minimal sequences derived from non-human immunoglobulins. In most cases, humanized antibodies are human immunoglobulins (receptor antibodies), wherein residues from the receptor hypervariable region are replaced by hypervariable region residues from non-human species such as mice, rats, rabbits, or non-human primates (donor antibodies) with desired specificity, affinity, and ability. In some cases, the framework region (FR) residues of human immunoglobulins are replaced by corresponding non-human residues. In addition, humanized antibodies may be included in residues that are not present in the receptor antibody or the donor antibody. These modifications are made in order to further improve antibody performance. In general, humanized antibodies will include substantially all of at least one, usually two variable domains, wherein all or substantially all of the hypervariable loops correspond to the hypervariable loops of non-human immunoglobulins, and all or substantially all of the FRs are FRs of human immunoglobulin sequences. Humanized antibodies typically include modified human immunoglobulin constant regions (Fc).
[0194] Non-human antibodies can be humanized by any method known in the art. In one method, non-human complementary determining regions (CDRs) are inserted (grafted) into human antibodies or consensus antibody framework sequences. Further changes can then be introduced into the antibody framework to adjust affinity or immunogenicity.
[0195] For example, U.S. Pat. No. 5,585,089 of Queen et al. discloses a humanized immunoglobulin and a method for preparing the same, wherein the humanized immunoglobulin comprises a complementary determining region (CDR) from a donor immunoglobulin and a heavy chain and heavy chain variable region framework from a human acceptor immunoglobulin heavy chain and light chain, wherein the humanized immunoglobulin comprises amino acids from a donor immunoglobulin framework outside of Kabat and Chothia CDRs, wherein the donor amino acids replace the corresponding amino acids in the acceptor immunoglobulin heavy chain or light chain framework. U.S. Pat. No. 5,225,539 of Winter also discloses a modified antibody or its antigen-binding fragment and a method for preparing the same, wherein the variable domain of the antibody or antigen-binding fragment has a framework region of a first immunoglobulin heavy chain or light chain variable domain and a complementary determining region of a second immunoglobulin heavy chain or light chain variable domain, wherein the second immunoglobulin heavy chain and light chain variable domain are different from the first immunoglobulin heavy chain or light chain variable domain in terms of antigen binding specificity, antigen binding affinity, species, class or subclass.
[0196] "Human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or prepared using any technology disclosed herein for preparing human antibodies. This definition of human antibody specifically excludes humanized antibodies comprising non-human antigen binding residues. Human antibodies can be produced using various techniques known in the art. In one embodiment, human antibodies are selected from a phage library, wherein the phage library expresses human antibodies (Vaughan et al., Nature Biotechnology 1996 14, 309-314; Sheets et al., PNAS (USA), 1998, 95, 6157-6162); Hoogenboom and Winter, J. Mol. Biol., 1991, 227, 381; Marks et al., J. Mol. Biol., 1991, 222, 581). Human antibodies can also be prepared by introducing human immunoglobulin loci into transgenic animals, such as mice in which endogenous immunoglobulin genes have been partially or completely inactivated. Following challenge, production of human antibodies is observed that closely resemble those observed in humans in all aspects including gene rearrangement, assembly, and antibody repertoire. This method is described, for example, in U.S. Pat. Nos. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, and in the following scientific publications: Marks et al., Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13:65-93 (1995). Alternatively, human antibodies can be prepared by immortalizing human B lymphocytes that produce antibodies against the target antigen (such B lymphocytes can be recovered from an individual or immunized in vitro). See, for example, Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147 (1): 86-95 (1991); and U.S. Pat. No. 5,750,373.
[0197] The term "site-directed mutagenesis" as used herein refers to an in vitro procedure that uses custom-designed oligonucleotide primers to confer desired mutations in double-stranded DNA plasmids. The most widely used method introduces mutations into plasmids by inverse PCR using standard primers. For example, one of the methods exploits the special affinity of overlapping primers to introduce specific desired substitutions.
[0198] Affinity is the strength with which a single molecule binds to its ligand. It is usually expressed as the equilibrium dissociation constant (K D ) to measure and report, K D Used to assess and rank the strength of bimolecular interactions. The binding of an antibody to its antigen is a reversible process, and the rate of the binding reaction is proportional to the concentration of the reactants.
[0199] K D is the equilibrium dissociation constant between the antibody and its antigen, i.e., k off / k on The ratio of n. K D The value is negatively correlated with affinity. D The value is related to the antibody concentration (the amount of antibody required for a specific experiment), so K D The lower the value (lower the concentration), the higher the affinity of the antibody.
[0200] Ki refers to the inhibition constant, which is used to describe the binding affinity of a molecule to its ligand (e.g., antibody to antigen, enzyme to ligand). D , Ki also represents the dissociation constant, but more narrowly refers to the binding of a ligand whose binding reduces the activity of the binding molecule. The binding equilibrium described by the Ki value depends on the kinetic mechanism of inhibition.
[0201] Ki is measured by inhibition kinetics, for example by competitive ELISA, whereas when binding is measured more directly, for example by surface plasmon resonance (SPR), "K D " is preferred (Scarano S, Mascini M, Turner AP, Minunni M, Surface plasmon resonance imaging for affinity-based biosensors, Biosens Bioelectron. 2010, 25: 957-66). Lower K D and K i Values reflect higher affinity and inhibition.
[0202] The Fc region of monoclonal antibodies serves as an important bridge between adaptive and innate immune responses. When the antigen expressed on the surface of cancer cells, virus-infected cells or invading pathogens is recognized by specific antibodies, the cells or pathogens become coated with the antibodies. The Fc region of antibodies attached to these surfaces helps eliminate the target by different mechanisms. First, it can interact with the C1 molecule of the complement system and trigger the activation of the classical pathway of the complement system. It can also recruit phagocytes through Fc receptors and activate phagocytosis (ADCP) pathways and ADCC mediated by NK cells, macrophages and other effector cells. In these mechanisms, studies on rituximab (anti-CD20 antibody) and trastuzumab (anti-HER2 / neu antibody, also referred to as Herceptin) show that ADCC / ADCP is the key mechanism of action to eliminate cancer cells.
[0203] The term "activation of dendritic cells (DCs)" as used hereinafter refers to a process triggered by pathogens, inflammatory stimuli or T helper lymphocytes. The activation of DCs triggers a variety of changes that convert activated DCs into the most efficient antigen presenting cells. One of these changes is that the surface expression of costimulatory molecules of T cells such as CD80 and CD86 (which serve as markers of activated DCs) is significantly increased.
[0204] The Fc region modifications of the present invention may be performed by site / oligonucleotide directed mutagenesis, resulting in the substitution, addition or deletion of at least one amino acid residue of the polypeptide, or at the level of glycosylation of the Fc region, for example by removing or adding at least one oligosaccharide (N-glycan) moiety, or more specifically by reducing fucose units (defucosylation).
[0205] The term "defucosylated antibody" as used hereinafter refers to an antibody having significantly reduced, ie, more than 50% reduced, fucose or no fucose on the glycan structure of the Fc region relative to the parent antibody comprising unmodified IgG1.
[0206] According to some embodiments of the invention, significantly reduced fucosylation refers to a fucose content or level in all glycan structures of at most about 40%.According to some embodiments, the antibody comprises 20-40% fucose in all glycan structures on its Fc region.
[0207] Defucosylation, i.e., reduction of fucose content in antibody Fc, can be performed by any method known in the art, including in cell lines (e.g., CHO cells) in which the fucosylation machinery is genetically knocked out, blocked or altered. According to some embodiments, defucosylation is performed post-translationally.
[0208] Defucosylation can also be performed according to any of the following non-limiting methods:
[0209] (i) Fucosyltransferase (FUT) inhibitors, such as the L-fucose analog 2-fluoroperacetylated fucose (2FF), which interferes with the normal synthesis of GDP-fucose and inhibits core fucosylation (Mishra N et al., "Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody", J Biotechnol. 2020; Zhou Y et al., "Inhibition of fucosylation by 2-fluorofucosesuppresses human liver cancer HepG2 cell proliferation and migration as wellas tumor formation", Sci Rep 7, 11563 (2017).
[0210] (ii) Lec13 cells as a host cell line for producing defucosylated antibodies (Shields RL et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity, J Biol Chem. 2002, 277: 26733–40).
[0211] (iii) GDP-keto-6-deoxymannose 3,5-epimerase / 4-reductase (FX) knockout CHO cell lines to produce antibodies with fully defucosylated N-glycans (Louie S. et al., FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality, Biotechnol Bioeng. 2017, 114: 632–44).
[0212] (iv) FUT8 (fucosyltransferase 8) - / - cell line, which was shown to express completely defucosylated antibodies compared to the same antibodies produced in the parental cell line (Yamane-Ohnuki, N. et al., Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity, Biotechnology and bioengineering, 87, 614-622).
[0213] (v) Rat hybridoma YB2 / 0 cells, which have lower levels of Fut8 (fucosyltransferase 8) mRNA compared with CHO cells (Shinkawa T. et al., The absence of fucosebut not the presence of galactose or bisecting N-acetylglucosamine of humanIgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity, J Biol Chem. 2003 Jan 31, 278(5): 3466-73).
[0214] (vi) FUT8 siRNA CHO cells (Mori K. et al., Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using, Biotechnol Bioeng, 2004, 88: 901-8).
[0215] (vii) CHO-gmt3 (CHO glycosylation mutant 3) cells, which show a complete lack of core fucose on N-glycans attached to EPO Fc fusion protein and IgG1 antibodies produced in CHO-gmt3 cells (Chan KF et al., Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies, Biotechnol J. 2016, 11: 399–414).
[0216] (viii) CHO cells overexpressing both GnT III and αManII, which produce the highest levels of bisected and defucosylated glycans on IgG antibodies (Ferrara C. et al., Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1,4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II, Biotechnol Bioeng, 2006, 93:851–61).
[0217] (ix) Small molecules that inhibit antibody fucosylation to complement existing platforms involving genetic engineering of cell lines for the production of defucosylated antibodies (Okeley et al., Development of orally active inhibitors of protein and cellular fucosylation, Proc Natl Acad Sci USA, 2013, 110:5404–9).
[0218] (x) Alternative expression platforms, such as plants (Loos A., IgG-Fc glycoengineering in non-mammalian expression hosts, Arch Biochem Biophys, 2012, 526: 167–73).
[0219] According to some embodiments, defucosylation is performed by adding 20-600 μM 2-deoxy-2-fluoro-L-fucose to the transfection medium.
[0220] Antibody fucose content and defucosylation rate can be determined by any method known in the art, including but not limited to mass spectrometry.
[0221] Sequence identity is the percentage of amino acids or nucleotides that are fully matched between two different sequences. Sequence similarity allows conservative substitutions of amino acids to be determined as identical amino acids. The polynucleotide sequences described herein can be codon optimized for expression in specific cells (e.g., human cells). Codon optimization does not change the encoded amino acid sequence of the antibody chain, but may, for example, improve expression in cells.
[0222] Variants, analogs and derivatives of the antibody sequences are also within the scope of the present application. They include, but are not limited to, conservative and non-conservative substitutions, insertions and deletions of amino acids within the sequence. Such modifications and the antibody analogs or variants produced therefrom are within the scope of the present invention, as long as they confer or even improve the binding properties to hGITR and human FcγR.
[0223] As used herein, the term "antibody variant" refers to an antibody derived from another antibody by one or more conservative amino acid substitutions and / or by changes in the glycosylation content of the Fc region. Variants according to the present invention can be prepared to retain the overall molecular structure of the encoded protein. The skilled artisan will recognize some reasonable substitutions, taking into account the properties of the individual amino acids that make up the disclosed protein products.
[0224] Conservative amino acid substitutions known to those skilled in the art are within the scope of the present invention. Conservative amino acid substitutions include replacing one amino acid with another amino acid having the same type of functional group or side chain (e.g., aliphatic, aromatic, positively charged, negatively charged). These substitutions can enhance oral bioavailability, permeability, and targeting to a particular cell population, immunogenicity, etc. Those skilled in the art will recognize that the changes, additions, or deletions made to a peptide, polypeptide, or protein sequence, each substitution, deletion, or addition of a single amino acid or a small portion of amino acids in the encoded sequence are "conservatively modified variants," wherein the changes result in amino acids being replaced by chemically similar amino acids. Conservative substitution tables that provide functionally similar amino acids are well known in the art. For example, according to a table known in the art, the following six groups each contain amino acids conservatively substituted with each other:
[0225] 1) Alanine (A), serine (S), threonine (T);
[0226] 2) Aspartic acid (D), glutamic acid (E);
[0227] 3) Asparagine (N), glutamine (Q);
[0228] 4) Arginine (R), Lysine (K);
[0229] 5) isoleucine (I), leucine (L), methionine (M), valine (V); and
[0230] 6) Phenylalanine (F), tyrosine (Y), tryptophan (W).
[0231] As used herein, the term "antibody conjugate" refers to any molecule comprising an antibody of the invention. For example, a fusion protein in which an antibody is linked to another entity (eg, an anticancer drug or a recognizable moiety) is considered an antibody conjugate.
[0232] The term "nucleic acid" refers to a single-stranded or double-stranded sequence (polymer) of deoxyribonucleotides or ribonucleotides. In addition, unless otherwise specified, polynucleotides include variants of natural polynucleotides. According to one embodiment, nucleic acid can be selected from deoxyribonucleic acid (DNA), ribonucleic acid (RNA), peptide nucleic acid (PNA), locked nucleic acid (LNA) and analogs thereof, but is not limited thereto. The term covers single-stranded or double-stranded DNA, RNA and chemical modifications thereof.
[0233] The term "polynucleotide" as used herein refers to a long nucleic acid comprising more than 150 nucleotides.
[0234] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein.
[0235] The antibodies described herein are encoded by nucleic acids. In certain embodiments, nucleic acids are components of vectors, which can be used to transfer polynucleotides encoding polypeptides into cells. The term "vector" as used herein refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. One type of vector is a genomic integration vector or "integration vector", which can become integrated into the chromosomal DNA of a host cell. Another type of vector is an "episomal" vector, such as a nucleic acid capable of extrachromosomal replication. A vector capable of directing the expression of a gene operably connected thereto is referred to herein as an "expression vector". Suitable vectors include plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, viral vectors, etc. In expression vectors, regulatory elements such as promoters, enhancers, and polyadenylation signals for controlling transcription can be derived from mammals, microorganisms, viruses, or insect genes. The ability to replicate in a host, which is usually conferred by a replication origin, and selection genes that facilitate identification of transformants can also be additionally introduced. Vectors derived from viruses such as slow viruses, retroviruses, adenoviruses, adeno-associated viruses, etc. can be used. Plasmid vectors can be linearized to be integrated into a chromosomal position. The vector may comprise a sequence that directs site-specific integration into a defined position or a restricted set of sites in the genome (eg AttP-AttB recombination). In addition, the vector may comprise a sequence derived from a transposable element.
[0236] The nucleic acids encoding the antibodies described herein can be used to infect, transfect, transform or otherwise make suitable cells genetically modified by the nucleic acids, thereby being able to produce antibodies for commercial or therapeutic use. Standard cell lines and methods for producing antibodies from large-scale cell cultures are known in the art. In certain embodiments, the cells are eukaryotic cells. In certain embodiments, the eukaryotic cells are mammalian cells. In certain embodiments, the mammalian cells are cell lines that can be used to produce antibodies, and are Chinese hamster ovary cells (CHO), NSO mouse myeloma cells or Cells. In certain embodiments, nucleic acids encoding antibodies are integrated into genomic loci of cells that can be used to produce antibodies. In certain embodiments, a method of preparing an antibody is described herein, comprising culturing cells comprising nucleic acids encoding antibodies under in vitro conditions sufficient to produce and secrete the antibody.
[0237] Any known method for producing recombinant antibodies can be used to produce the antibodies of the present invention. According to one method, cells transformed with nucleotide sequences encoding antibody polypeptides are cultured under effective conditions that allow a large amount of expression of the one or more recombinant polypeptides. Effective culture conditions include, but are not limited to, effective culture media, bioreactors, temperature, pH values, and oxygen conditions that allow protein production. Effective culture media refers to any culture media in which cells are cultured to produce the recombinant polypeptides of the present invention. Such culture media typically include an aqueous solution with assimilable carbon, nitrogen, and phosphate sources and suitable salts, minerals, metals, and other nutrients (e.g., vitamins). The cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter plates, and petri dishes. Cultivation can be carried out at a temperature, pH, and oxygen content suitable for recombinant cells. Such culture conditions are within the professional knowledge of those of ordinary skill in the art.
[0238] Depending on the vector and host system used for production, the resulting polypeptide of the invention may be retained within the recombinant cell, secreted into the fermentation medium, secreted into the space between two cell membranes, or retained on the outer surface of the cell or on a viral membrane.
[0239] After a predetermined period of culture, the recombinant antibody is recovered, for example, by collecting the entire fermentation medium containing the antibody polypeptide, with or without additional separation or purification steps.
[0240] If the antibody polypeptide is expressed in cells, the cell membrane is preferably disrupted to release the polypeptide using methods known in the art, including homogenization.
[0241] Any method known in the art for expressing and purifying antibodies can be used to prepare the antibodies of the present invention, including but not limited to the methods described in Vazquez-Lombardi et al., 2018, nature Protocols, 13, 1, 99-117.
[0242] It should be emphasized that different sequencing methods for the same protein or nucleotide sequence may result in slightly different sequences, especially at the end of the sequence, due to technical problems and different primers.
[0243] Nonetheless, the antibodies of some embodiments of the invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, protein A / G / L separation, mixed mode chromatography, metal affinity chromatography, lectin affinity chromatography, chromatofocusing, and differential solubilization.
[0244] Pharmacology and therapeutic approaches
[0245] In medicaments and pharmaceutical preparations, the active agent is preferably used together with one or more pharmaceutically acceptable carriers and optionally any other therapeutic ingredients. The carrier must be pharmaceutically acceptable in the sense that it is compatible with the other ingredients of the formulation and is not overly harmful to its receptor. As described above, the active agent is provided in an amount effective to achieve the desired pharmacological effect and in an amount suitable to achieve the desired exposure.
[0246] As is well known, the antibody of the present invention as an active ingredient is dissolved, dispersed or mixed in a pharmaceutically acceptable excipient that is compatible with the active ingredient. Suitable excipients are, for example, water, saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, etc. and combinations thereof. Other suitable carriers are well known to those skilled in the art. In addition, if necessary, the composition may contain a small amount of auxiliary substances such as wetting agents or emulsifiers, pH buffers.
[0247] According to some embodiments, the pharmaceutical composition comprises 1-50 mg / ml of an anti-hGITR antibody. According to some embodiments, the pharmaceutical composition comprises a basic amino acid. According to some embodiments, the pharmaceutical composition comprises a sugar. According to some embodiments, the pharmaceutical composition comprises a surfactant. According to some embodiments, the pharmaceutical composition comprises a basic amino acid, a sugar, and a surfactant. According to some embodiments, the pharmaceutical composition comprises (i) 1-10 mg / ml of a basic amino acid; (ii) 10-200 mg / ml of a sugar; (iii) 0.01-1 mg / ml of a surfactant; (iv) 1-50 mg / ml of an anti-hGITR antibody.
[0248] According to some embodiments, the basic amino acid is selected from the group consisting of histidine, arginine, lysine and ornithine. Each possibility represents a separate embodiment of the present invention.
[0249] The term "sugar" refers to monosaccharides, disaccharides and polysaccharides. Examples of sugars include, but are not limited to, sucrose, trehalose, dextrose, etc. According to some embodiments, the sugar is selected from sucrose, trehalose, glucose, dextrose and maltose. Each possibility represents an independent embodiment of the present invention. According to some embodiments, the composition comprises 10-200, 10-100, 50-150 or 70-100 mg / ml of sugar. Each possibility represents an independent embodiment of the present invention.
[0250] According to other embodiments, the composition comprises a polyol, including but not limited to mannitol and sorbitol.
[0251] According to some embodiments, the surfactant is non-anionic. According to some embodiments, the surfactant is selected from polysorbates, sorbitan esters and poloxamers. Each possibility represents an independent embodiment of the present invention. According to some embodiments, the composition comprises 0.01-10, 0.01-1, 0.05-5 or 0.1-1 mg / ml of surfactant. Each possibility represents an independent embodiment of the present invention.
[0252] Typically, the antibody of the present invention and its conjugate are suspended in a sterile saline solution for therapeutic use. Alternatively, the pharmaceutical composition can be formulated to control the release of active ingredients or extend its presence in the patient's system. A large number of known suitable drug delivery systems include, for example, implantable drug release systems, hydrogels, hydroxymethyl cellulose, microcapsules, liposomes, microemulsions, microspheres, etc. Controlled release formulations can be prepared by using polymer complexing or adsorption according to the molecule of the present invention. For example, biocompatible polymers include a matrix of polyethylene-to-vinyl acetate and a matrix of a polyanhydride copolymer of stearic acid dimer and sebacic acid. The rate at which the molecule (i.e., antibody) is released from this type of matrix depends on the molecular weight of the molecule, the amount of the molecule in the matrix, and the size of the dispersed particles.
[0253] The pharmaceutical compositions of the present invention are formulated for administration by any suitable means, such as intravenous, subcutaneous, intramuscular, oral, topical, intranasal, intraarterial, intraarticular, intralesional, intratumoral or parenteral. Typically, intravenous (iv) administration is used to deliver the antibody. In some embodiments, the antibody or antibody conjugate is administered by infusion.
[0254] According to one aspect, the present invention provides a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the antibody or antibody conjugate described herein.
[0255] As used herein, the terms "subject," "individual," or "patient" refer to an individual diagnosed with, suspected of having, or at risk for developing at least one disease that the described compositions and methods can be used to treat. According to some embodiments, the individual is a mammal. According to some embodiments, the individual is a human.
[0256] It will be apparent to one of ordinary skill in the art that a therapeutically effective amount of a molecule according to the invention will depend, inter alia, on the schedule of administration, the unit dose of the molecule administered, whether the molecule is administered in conjunction with other therapeutic agents, the immune status and health of the patient, the therapeutic activity of the molecule administered, its persistence in the blood circulation, and the judgment of the treating physician.
[0257] The term "therapeutically effective amount" as used herein refers to the amount of a drug that is effective in treating a disease or disorder in a mammal. In the case of cancer, a therapeutically effective amount of a drug can reduce the number of cancer cells, reduce tumor size, inhibit (i.e., slow down and preferably stop to a certain extent) cancer cell infiltration into peripheral organs, inhibit (i.e., slow down and preferably stop to a certain extent) tumor metastasis, inhibit tumor growth to a certain extent, and / or alleviate one or more symptoms associated with the disorder to a certain extent. To the extent that a drug can prevent the growth of existing cancer cells and / or kill existing cancer cells, it may be cell inhibitory and / or cytotoxic. For cancer therapy, in vivo efficacy can be measured, for example, by assessing survival duration, disease progression time (TTP), response rate (RR), response duration, and / or quality of life.
[0258] The term "cancer" refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Cancers suitable for treatment by the present invention include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias or lymphoid malignancies. More specific examples of these cancers include squamous cell carcinoma, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous carcinoma), peritoneal cancer, hepatocellular carcinoma, gastric cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, and various types of head and neck cancer, as well as B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL)); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL L; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-dividing cell NHL; large mass lesion NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with nevus hamartomatosis, edema (e.g., edema associated with brain tumors), and Meigs syndrome. According to some embodiments, the cancer is selected from non-small cell lung cancer (NSCLC), renal cell carcinoma, melanoma, glioblastoma, colorectal cancer, breast cancer, and ovarian cancer. Cancer conditions suitable for treatment of the present invention include metastatic cancers.
[0259] The pharmaceutical composition according to the present invention can be co-administered or combined with an anticancer composition.
[0260] The term "combination" or "combination therapy" as used herein may refer to the simultaneous administration of the products to be combined or the sequential administration of the products to be combined. As described herein, when the combination involves the sequential administration of products, the products may be administered in any time order.
[0261] As used herein, the term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in whom the disorder is to be prevented.
[0262] According to some embodiments, the method of treating cancer comprises administering the pharmaceutical composition as part of a treatment regimen that includes administering at least one additional anti-cancer agent or treatment.
[0263] According to some embodiments, the anticancer agent is selected from antimetabolites, mitotic inhibitors, taxanes, topoisomerase inhibitors, topoisomerase II inhibitors, asparaginases, alkylating agents, antitumor antibiotics, immunomodulators, checkpoint inhibitors, antibodies targeting tumor antigens, and combinations thereof. Each possibility represents an independent embodiment of the present invention.
[0264] According to some embodiments, the antimetabolite is selected from cytarabine, fludarabine, fluorouracil, mercaptopurine, methotrexate, thioguanine, gemcitabine and hydroxyurea. According to some embodiments, the mitotic inhibitor is selected from vincristine, vinblastine and vinorelbine. According to some embodiments, the topoisomerase inhibitor is selected from topotecan and irinotecan. According to some embodiments, the alkylating agent is selected from busulfan, carmustine, lomustine, chlorambucil, cyclophosphamide, cisplatin, carboplatin, ifosfamide, nitrogen mustard, melphalan, thiotepa, dacarbazine and procarbazine. According to some embodiments, the antitumor antibiotic is selected from bleomycin, actinomycin D, daunorubicin, doxorubicin, idarubicin, mitomycin, mitoxantrone and plicamycin. According to some embodiments, the topoisomerase II inhibitor is selected from etoposide and teniposide. Each possibility represents an independent embodiment of the present invention.
[0265] According to some specific embodiments, the additional anticancer agent is selected from bevacizumab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, topotecan hydrochloride, thiotepa and combinations thereof. Each possibility represents an independent embodiment of the present invention.
[0266] The antibodies according to the invention may be used as part of a combination therapy with at least an immunomodulator, activated lymphocytes, a kinase inhibitor or a chemotherapeutic agent.
[0267] According to some embodiments, the anti-cancer agent is an immunomodulatory agent, either an agonist or an antagonist, such as an antibody to an immune checkpoint inhibitor.
[0268] Checkpoint immunotherapy blockade has proven to be an exciting new venue for cancer treatment. Immune checkpoint pathways consist of a series of co-stimulatory and inhibitory molecules that work together to maintain self-tolerance and protect tissues from damage by the immune system under physiological conditions. Tumors exploit certain checkpoint pathways to evade the immune system. Therefore, inhibition of these pathways has emerged as a promising anticancer therapeutic strategy.
[0269] The anti-cytotoxic T lymphocyte 4 (CTLA-4) antibody ipilimumab (approved in 2011) was the first immunotherapeutic agent to show benefit in cancer patients. The antibody interferes with inhibitory signals during antigen presentation to T cells. The anti-programmed cell death 1 (PD-1) antibody pembrolizumab (approved in 2014) blocks negative immune regulatory signaling by the PD-1 receptor expressed by T cells. In 2014, an additional anti-PD-1 agent filed for regulatory approval for the treatment of non-small cell lung cancer (NSCLC). Currently, active research is exploring many other immune checkpoints, including: CEACAM1, NKG2A, B7-H3, B7-H4, VISTA, lymphocyte activation gene 3 (LAG3), CD137, OX40 (also known as CD134), and killer cell immunoglobulin-like receptors (KIRs).
[0270] According to other embodiments, the additional anticancer agent is a chemotherapeutic agent. Chemotherapeutic agents that can be administered together with or alone the antibodies according to the invention may include any such agent known in the art that exhibits anticancer activity, including but not limited to: mitoxantrone, topoisomerase inhibitors, spindle toxins from Vinca roseus: vinblastine, vincristine, vinorelbine (paclitaxel), paclitaxel, docetaxel; alkylating agents: nitrogen mustard, chlorambucil, cyclophosphamide, melphalan, ifosfamide; methylamine Pterin; 6-mercaptopurine; 5-fluorouracil, cytarabine, gemcitabine; podophyllotoxins: etoposide, irinotecan, topotecan, dacarbazine; antibiotics: doxorubicin (adriamycin), bleomycin, mitomycin; nitrosoureas: carmustine (BCNU), lomustine, epirubicin, idarubicin, daunorubicin; inorganic ions: cisplatin, carboplatin; interferon, asparaginase; hormones: tamoxifen, leuprolide, flutamide and megestrol acetate.
[0271] According to some embodiments, the chemotherapeutic agent is selected from alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthraquinone-substituted ureas, methylhydrazine derivatives, adrenocortical inhibitors, adrenocortical steroids, progestins, estrogens, antiestrogens, androgens, antiandrogens and gonadotropin-releasing hormone analogs. According to another embodiment, the chemotherapeutic agent is selected from 5-fluorouracil (5-FU), leucovorin (LV), irinotecan, oxaliplatin, capecitabine, paclitaxel and docetaxel. One or more chemotherapeutic agents can be used.
[0272] According to yet another aspect, the present invention provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antibody conjugate according to the present invention.
[0273] The toxicity and efficacy of the compositions described herein can be determined by standard pharmaceutical procedures in cell culture or experimental animals, for example, by determining the IC50 (concentration providing 50% inhibition) and the highest tolerated dose of the test compound. The data obtained from these cell culture assays and animal studies can be used to formulate a dosage range for humans. The dosage may vary, in particular, due to the dosage form adopted, the selected dosing regimen, the composition of the medicament used for treatment, the route of administration used, and other relevant factors. The exact formulation, route of administration, and dosage can be selected by an individual physician according to the patient's condition. Depending on the severity and responsiveness of the condition to be treated, administration may also be a single administration of a sustained-release composition, the course of which lasts for several days to several weeks, or until a cure is achieved or a reduction in the disease state is obtained. Of course, the amount of the composition to be administered will depend on the subject being treated, the severity of the ailment, the mode of administration, the judgment of the prescribing physician, and all other relevant factors.
[0274] The term "administering" or "applying" a substance, compound or medicament to a subject can be performed using one of various methods known to those skilled in the art. For example, a compound or medicament can be administered enterally or parenterally. Enteral administration refers to administration through the gastrointestinal tract, including oral, sublingual or rectal administration. Parenteral administration includes intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, ocular, sublingual, intranasal, inhalation, intraspinal, intracerebral and transdermal (by absorption, such as through a skin catheter) administration. The compound or medicament can also be suitably introduced by a refillable or biodegradable polymer device or other device (such as a patch and pump or a formulation that provides an extended, slow or controlled release of the compound or medicament). Administration can also be performed, for example, once, multiple times and / or over one or more extended time periods. In some embodiments, administration includes direct administration (including self-administration) and indirect administration (including prescribing behavior). For example, as used herein, a doctor who instructs a patient to self-administer or let others administer and / or provides a drug prescription for a patient is administering the drug to the patient.
[0275] The antibodies are typically administered in the range of about 0.1 to about 50 mg / kg of patient body weight, typically about 0.5 to about 20 mg / kg, typically about 1 to about 10 mg / kg. In this regard, antibodies having a circulation half-life of at least 12 hours, preferably at least 4 days, and more preferably up to 21 days are preferably used. In some cases, it may be advantageous to administer a large loading dose during treatment followed by regular (e.g., weekly) maintenance doses. The antibodies may also be delivered by sustained release delivery systems, pumps, and other known delivery systems for continuous infusion.
[0276] The term "about" means that an acceptable error range for the particular value should be assumed, for example up to 5% or 10%.
[0277] References without a specific number are used herein interchangeably with one or more and mean one or more.
[0278] The term "and / or" is used to indicate that one or both of the stated situations may occur, for example A and / or B includes (A and B) and (A or B).
[0279] The term "or" as used herein indicates that alternatives can be combined where appropriate; that is, the term "or" includes each listed alternative individually as well as combinations thereof if the combinations are not mutually exclusive.
[0280] The terms "comprising", "including", "having" and "containing" are used interchangeably herein and have the meaning of "consisting at least in part of...". When interpreting each statement in this specification including the term "comprising", other features besides the one or more features preceding the term may also be present. Related terms such as "comprising" should be interpreted in the same manner. The terms "having" and "comprising" may also encompass the meanings of "consisting of..." and "consisting essentially of..." and may be replaced by these terms. The term "consisting of..." does not include any components, steps or procedures that are not explicitly described or listed. The term "consisting essentially of..." means that the composition or component may include additional ingredients, but only if the additional ingredients do not substantially change the basic and novel features of the claimed composition or method.
[0281] In order to more fully illustrate some embodiments of the present invention, the following methods and examples are presented. They should in no way be construed as limiting the scope of the present invention.
[0282] Generally, the nomenclature used herein and the laboratory procedures used in the present invention include molecular, biochemical, microbiological, immunological and recombinant DNA techniques. Such techniques are well known in the art. For the convenience of the reader, other general references citing well-known procedures are provided throughout this article.
[0283] Example
[0284] Materials and methods
[0285] ELISA assay
[0286] The binding specificity and affinity of the antibody variants were determined by ELISA using recombinant mouse or human GITR (SinoBiological). ELISA plates (Nunc) were coated with the described recombinant GITR (1 μg / mL / well) overnight at 4°C. All sequential steps were performed at room temperature in phosphate-buffered saline (PBS) supplemented with 2% bovine serum albumin (BSA). After washing, the plates were blocked for 1 hr and then incubated with serially diluted antibody samples for 1 hr. After washing, the plates were incubated with HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch) for 1 hr. Detection was performed by TMB soluble reagent (3,3′,5,5′-tetramethylbenzidine, ScyTek Laboratories) and the reaction was stopped by adding 0.18 M sulfuric acid. The absorbance at 450 nm was recorded immediately using a SpectraMax Plus spectrophotometer (Molecular Devices), and the background absorbance from the negative control sample was subtracted.
[0287] For FcγR binding ELISA, the above protocol was modified as follows: Human FcγR soluble extracellular domain (2 μg / ml / well) was immobilized to the plate. After washing, the plate was blocked with PBS containing 10% BSA for 40 minutes and then incubated with serially diluted antibodies for 2 hours.
[0288] In vivo studies in mice
[0289] C57BL / 6J mice were purchased from Harlan Laboratories. FcγR humanized mice (mFcγRα - / - 、Fcgr1 - / - hFcγRI + hFcγRIIAR 131+ hFcγRIIB + hFcγRIIIAF 158+ and hFcγRIIIB + ) in a C57Bl / 6J background and were generated as described by Rankin CT et al. (CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma, Blood, 2006, 108, 2384–91).
[0290] To evaluate the modulation of immune cells following administration of anti-hGITR Fc region variants, mice humanized for FcγR and hGITR (huFcγR / hGITR) were generated.
[0291] For pharmacokinetic assays to evaluate the effect of Fc region modifications on antibody half-life in vivo, human FcγR mice bearing MC38 (mouse colon adenocarcinoma) tumors were injected with the hIgG1 Fc region variant of the DTA-1 anti-mouse GITR antibody (200 μg / mouse) and bled at indicated time points.
[0292] To evaluate antitumor activity (using either a single or first challenge), FcγR humanized mice inoculated with MC38 cells were treated with a chimeric human Fc region variant based on the Fab of the anti-mGITR antibody DTA-1. Mice aged 8-10 weeks were anesthetized and MC38 cells (2×10 6 Tumor volume was measured every 2-3 days using an electronic caliper and the formula (L2 2× L1) / 2 is reported as volume, where L1 is the longest diameter and L2 is the shortest diameter. After tumor inoculation, mice were randomized according to tumor size (day 0), with a mean of 55 mm 3 or 115mm 3 (unless otherwise indicated), and received intraperitoneal (ip) injections of Ab or PBS. Mice were treated with 100 μg / mouse of hIgG1-containing antibody variants and additional antibody treatments on days 3 and 6 as indicated.
[0293] For rechallenge experiments to assess long-term immune and memory responses, mice with a complete response and rejection of the primary tumor (tumor-free mice) were followed for 62 days after the start of treatment and then inoculated with MC38 tumor cells (2×10 6 Re-vaccination.
[0294] For CD4 / CD8 depletion experiments, several tumor-free mice were injected with antibodies against CD4 and / or CD8 prior to rechallenge.
[0295] Tissue processing and flow cytometry
[0296] For functional experiments, mice were challenged and treated as described above and sacrificed on day 8 unless otherwise stated. Spleens were dissected through a 70 μm nylon cell strainer, incubated with erythrocyte lysis buffer (Sigma) and washed. Tumors were mechanically minced into small pieces and transferred to a GentleMACS containing 0.33 mg / ml DNase (Sigma-Aldrich) and 0.27 mg / ml Liberase TL (Roche). TM C tube (Milteny). TM Octo dissociator program "m_impTumor_02_01" (Milteny) was performed twice, followed by incubation at 37°C for 40 minutes using continuous rotation at 25 rpm. Program "m_impTumor_03_01" (Milteny) was performed twice before being dispersed and washed through a 70 μm nylon cell strainer. Lymph nodes were dissected and washed through a 70 μm nylon cell strainer.
[0297] Different cell populations were identified after exclusion of dead cells using the Live / Dead Fix Blue Dead Cell Stain Kit (Invitrogen). For intracellular staining, cells were fixed and permeabilized using the Foxp3 Fix / Perm Buffer Kit (BioLeagend). CountBright TMAbsolute counting beads (Life Technologies). Cell populations were defined by the following markers (BioLegend): dendritic cells (CD11b + CD11c + MHCII + F4 / 80 - ), NK cells (NKp46 + CD3 - ), CD8 T cells (CD3 + CD8 + CD4 - ), CD4 T cells (CD3 + CD4 + CD8 - ), CD4 effector T cells (CD3 + CD4 + CD8 - Foxp3 - CD44 + ) and CD4 regulatory T cells (CD3 + CD4 + CD8 - Foxp3 + ).
[0298] Mass spectrometry
[0299] The samples were trypsinized using the S-trap method, followed by HILIC enrichment of glycopeptides. The resulting peptides were analyzed using nanoflow liquid chromatography (nanoAcquity) coupled to a high-resolution, high-quality mass spectrometer (Fusion Lumos). The resulting data were searched against human IgG1 glycosylated peptides and human Fc glycan databases using Byonic. IDs were manually verified and quantified using Skyline (v19.1.0.193). The experiments were performed and analyzed by the INCPM unit of the Weizmann Institute of Science.
[0300] Determination of dissociation constant (KD) by surface plasmon resonance (SPR)
[0301] SPR experiments using Biacore TMThe antibodies were captured onto a Protein G chip using a T200 (Cytiva) instrument. All measurements were performed using PBS-Tween 0.05%. Antibodies were immobilized at a concentration of 5 μg / mL for 20 s at a flow rate of 10 μL / min. FcγRs were prepared at different concentration ranges: 0.78 nM–200 nM FcγRIIA, 2.34–600 nM FcγRIIIA and 2–500 nM FcγRIIB. Each concentration was injected at a flow rate of 30 μL / min for 180 s and left to dissociate for 340 s. After each cycle, the surface was regenerated with glycine buffer, pH 1.5. Background binding to a blank immobilized channel was subtracted from each binding event. Data were fit to a two-state 1:1 binding model using the T200 Evaluation Software and K was calculated. D The activation to inhibition affinity ratio of each variant was calculated as follows: K D Activate / K D inhibition.
[0302] Statistical analysis
[0303] When comparing two groups and when comparing groups in experiments evaluating cell type percentages, unpaired two-tailed t-tests were used. Data were analyzed using GraphPad Prism software (GraphPad), and p values < 0.05 were considered statistically significant, indicated in the figures as *p≤0.05, **p≤0.01, and ***p≤0.001. Asterisks indicate statistical comparisons as shown in the figure.
[0304] Example
[0305] Reference is now made to the following examples, which together with the above descriptions illustrate the invention in a non-limiting fashion.
[0306] Example 1. Generation and characterization of anti-GITR hIgG1 Fc region variants
[0307] To generate chimeric anti-mouse GITR antibodies with human IgG1 from rat anti-mouse DTA-1 clones, the variable regions of the heavy and light chains were sequenced and synthesized from the DTA-1 hybridoma clone (by BioBasic). To generate humanized anti-human GITR antibodies, the heavy chain (HC) and light chain (LC) sequences of the anti-hGITR antibody were used and synthesized (by BioBasic). The sequences were PCR amplified and cloned into a mammalian expression vector with human IgG1 constant regions. Figure 2 Shown are the gel electrophoresis results of HC and LC expression vectors after insertion of anti-GITR VH and VL. Figure 2Gel electrophoresis results of HC and LC expression vectors after insertion of anti-GITR VH and VL from TRX518 are shown (the gel is DTA-1). Lane 1 - 1 Kb molecular weight marker (Mw), Lane 2 - 100 bp Mw, Lane 3 - uncut expression vector, Lanes 4 and 5 - vectors with anti-GITR VH inserts, Lane 6 - vectors with anti-GITR VL and LC constant regions (Fc), Lane 7 - HC IgG1 expression vector with constant region (Fc), Lane 8 - HC IgG1 expression vector with constant region (Fc) with V11 mutation in the heavy chain constant region. Lane 9 - LC IgG1 expression vector. To generate Fc-modified variants of human IgG1, site-directed mutagenesis techniques were applied to generate predefined point mutations by PCR using specific primers listed in Table 1 (Agilent Technologies) according to the manufacturer's instructions.
[0308] Table 1. Primers used to generate Fc modified variants
[0309]
[0310] The mutated plasmid sequences were verified by direct sequencing (Life science core facility, Weizmann Institute of Science). To generate antibodies, heavy and light chain expression vectors were transiently transfected into Expi293 cells (ThermoFisher). Antibodies secreted into the supernatant were purified by G protein Sepharose 4 Fast Flow (GE Healthcare). The purified antibodies were dialyzed in PBS and sterile filtered (0.22 μm), and the purity was assessed by SDS-PAGE, followed by Imperial TM Blue staining (ThermoFisher) confirmed that all antibodies were expressed in the expected form. To generate defucosylated Fc region variants, 200 μM 2-deoxy-2-fluoro-L-fucose (Carbosynth) as a fucosyltransferase inhibitor was added to the transfection medium and to the supernatant one day after transfection. Figure 3A-3B The anti-GITR variants expressed were shown to be expressed with Imperial TM Blue stained SDS PAGE: lane 1 - molecular weight marker, lane 2 - anti-mGITR V11, lane 3 - defucosylated anti-mGITL, lane 4 - N279A, lane 5 - GAALIE, lane 6 - GASDALIE, lane 7 - G236A, lane 8 - anti-mGITR IgG1. Figure 3A The results of non-reducing SDS-PAGE are shown. Figure 3BThe results of reducing SDS-PAGE are shown.
[0311] To test whether the activity of anti-mouse GITR (mGITR) chimeric antibodies comprising human IgG1 requires interaction with hFcγR and to determine whether this interaction can be further engineered to optimize the activity of the parent antibody, the variable regions of the anti-mouse GITL (DTA-1) antibody were cloned into human IgG1. Different mutations were introduced into the CH2 domain of the Fc region by site-directed mutagenesis to generate a series of mutant hIgG1 anti-mGITR antibodies. Binding affinity was measured using SPR analysis using immobilized FcγR and soluble antibodies, and the results are shown in Table 2.
[0312] Table 2. Binding affinity of IgG Fc region variants to selected human FcγRs
[0313]
[0314] *Multiplier = K D (IgG1) / K D (Fc region variant). nb = no binding.
[0315] Following production, the binding affinity of the Fc region variants to mouse GITR was measured and validated by comparative ELISA. Figure 4 The results of ELISA assays of Fc region variants against mouse GITR are shown; IgG1 (filled circles), IgG1-V11 (filled squares), IgG1-N297A (inverted triangles), IgG1-G236A (diamonds), Afuco-IgG1 (triangles), IgG-GAALIE (asterisks), IgG1-GASDALIE (open squares), and Afuco-IgG1-G236A. Figure 4 As shown in , the chimeric anti-mGITR (Fab comprising DTA-1) hIgG1 Fc region variant showed similar binding affinity to the parent antibody, indicating that Fc region modifications did not impair binding to mouse GITR.
[0316] In addition, the binding affinity of anti-mGITR antibodies with modified human IgG1 to each FcγR was compared and assessed using comparative ELISA. Figures 5A-5DComparative ELISA results for binding of anti-mGITR Fc region variants are shown: IgG1 (filled circles), IgG1-V11 (filled squares), Afuco-IgG1 (triangles), IgG1-N297A (inverted triangles), IgG-GAALIE (open circles), IgG1-GASDALIE (open squares), and IgG1-G236A (open diamonds). Anti-mouse GITR antibodies with DTA-1 binding sites and modified human IgG1 exhibit differential binding affinities to the hFcγRs indicated. A human IgG1 variant with multiple Fc region mutations G236A / S239D / A330L / I332E (referred to as "GASDALIE") primarily enhances hFcRγIIIA binding, but also binds hFcγRIIA and hFcγRIIB. A similar variant without the S239D mutation (G236A / A330L / I332E, referred to as "GAALIE") lost binding to hFcγRIIB while retaining enhanced binding to hFcRγIIIA and hFcRγIIA. The variant "IgG1-G236A" showed selective enhancement of hFcγRIIA binding, and the "IgG1-V11" variant (G237D / P238D / H268D / P271G / A330R, GDPDHDPGAR) selectively enhanced hFcγRIIB, showing no binding to human FcγRIIIA. Due to modification of the glycosylation site, the deglycosylated FcγR null variant "IgG1-N297A" lacks the ability to participate in the hFcγR pathway. The IgG1 variant "Afuco-IgG1" containing post-translational glycoengineering of unmodified Fc-N297 enhances binding to hFcγRIIIA.
[0317] Two non-fucosylated forms of anti-GITR variants, IgG1 and IgG1-G236A, were produced using a fucosyltransferase inhibitor (2FF) that was added to the transfection medium of IgG1 and IgG1-G236A producing cells one day after transfection. Fucosylation was determined by mass spectrometry and the percentage of non-fucosylated forms is shown in Table 3. Antibody concentrations were measured using a NanoDrop machine.
[0318] Table 3. Percentage of non-fucosylated forms of anti-GITR antibodies
[0319] GITR variants % of non-fucosylated form Fold change (relative to IgG1) IgG1 ~0.6% Afuco-IgG1 ~74.2% ~123 Afuco-IgG1-G236A ~80.6% ~134
[0320] Example 2. Pharmacokinetics of anti-mGITR IgG1 Fc region variants
[0321] The effect of Fc region modification on the in vivo half-life of the antibody was tested. Human FcγR mice bearing MC38 tumors were injected with hIgG1 Fc region variants (200 μg / mouse) of anti-mGITR antibodies containing the Fab of DTA-1, and blood was taken at the specified time points. The serum was stored at -80°C until all time points were collected. The antibody concentration in serum was determined using a standard colorimetric ELISA assay. In brief, the assay plate was coated with recombinant mouse GITR (1 μg / mL, Sino Biological, #13643-H08H) and incubated overnight at 4°C. The plate was then blocked for 2 hours with PBS containing 10% FCS. Serial dilutions of serum were added to the plate and incubated for 2 hours. After washing, the plate was incubated for 1 hour with horseradish peroxidase-coupled anti-human IgG antibody (#109-035-088, Jackson IuimmunoResearch). The absorbance at 450 nm was immediately recorded using a SpectraMax Plus spectrophotometer (Molecular Devices), and the background absorbance from the negative control sample was subtracted. Figure 6 ELISA results for the in vivo half-life (PK assay) of the Fc modified variants are shown: IgG1 (filled circles), IgG1-V11 (filled squares), IgG1-N297A (inverted triangles), IgG1-G236A (open diamonds), Afuco-IgG1 (triangles) and Afuco-IgG1-G236A (open circles).
[0322] like Figure 6 As shown in , the in vivo half-life of the Fc modified variants was similar to that of the antibody with the parent IgG1, except that "IgG1-V11" showed reduced levels in the blood 4 days after injection.
[0323] Example 3. In vivo anti-tumor activity of anti-GITR hIgG1 Fc region variants
[0324] The anti-tumor activity of anti-mGITR hIgG Fc region variants was evaluated in vivo in FcγR humanized mice inoculated with MC38 (mouse colon adenocarcinoma) cells and treated with the human Fc region variant of DTA-1. FcγR humanized C57BL / 6J mice (mFcγRα - / - 、Fcgr1 - / - hFcγRI + hFcγRIIAR 131+ hFcγRIIB + hFcγRIIIAF 158+ and hFcγRIIIB+ 8-10 week old mice were anesthetized and implanted subcutaneously (sc) with MC38 cells (2×10 6 Tumor volume was measured every 2-3 days using an electronic caliper and the formula (L2 2 × L1) / 2, where L1 is the longest diameter and L2 is the shortest diameter. After tumor inoculation, mice were randomized according to tumor size (day 0), with a mean of 55 mm 3 (unless otherwise indicated) and received intraperitoneal (ip) injections of Ab or PBS. For anti-tumor activity, mice were treated with 100 μg / mouse of hIgG-containing anti-mGITR antibody (DTA-1 based) and received additional antibody treatments on days 3 and 6. For rechallenge experiments, tumor-free mice from all treatment groups were inoculated with MC38 tumor cells (2×10 6 The mice were followed for tumor progression and overall survival, and the results are depicted in Figures 7A-7H middle.
[0325] Tumor volume and survival rate of each test animal were evaluated for each human Fc region variant antibody, and the Fc variants were compared with the IgG1-N297A group using an unpaired two-tailed t-test. Each line represents one animal. The results are as follows: Untreated mice (n = 10), as expected, had no tumor-free mice ( Fig. 7A ); IgG1 treatment (n=8), 4 / 8 tumor-free mice ( Figure 7B ); IgG1-N297A treatment (n=10), 1 / 10 tumor-free mice ( Figure 7C ); IgG1-V11 treatment (n=10), 0 / 10 tumor-free mice ( Fig.7D ); IgG1-G236A treatment (n=9), 6 / 9 tumor-free mice ( Fig. 7E ); Afuco-IgG1 treatment (n=10), 8 / 10 tumor-free mice ( Figure 7F The average tumor volume of all tested animals for each Fc region variant is as follows: Figure 7G As shown in: Original (untreated, solid diamonds), IgG1 (solid circles), IgG1-N297A (inverted triangles), IgG1-G236A (open diamonds), and Afuco-IgG1 (triangles). The probability of survival over time (until 60 days after the start of treatment) was also followed and the results are presented in Figure 7HMiddle: untreated mice (untreated, black line), IgG1 (dashed line), IgG1-N297A (dashed line), IgG1-V11 (dashed line and dots), IgG1-236A (dashed line and two dots), Afuco-IgG1 (line ending in a vertical line segment). Figure 7H As shown in the literature, several treatments showed an improved survival probability, 80% for Afuco-IgG1, 66.6% for IgG1-G236A, and 50% for IgG1. Treatment with the Fc-engineered or glycoengineered variants IgG1-G236A and Afuco-IgG1 resulted in a reduction in tumor growth and an improvement in overall survival compared to other Fc region variants.
[0326] To assess the ability of anti-GITR therapy to mediate long-term immune and memory responses, tumor-free mice from all treatment groups were re-challenged. Mice with complete responses and primary tumor rejection were followed for 62 days after treatment initiation and then re-inoculated on the opposite flank with 2 × 10 6 MC38 tumor cells without any additional treatment. The tumor progression and overall survival of the mice were tracked and the results are as follows: Tumor volume ( Fig. 8A ) and the survival probability ( Figure 8B ), calculated for each previous Fc region variant treatment (tumor-free animals). Fig. 8A : Naive (untreated, solid diamonds, n=9), IgG1 (solid circles, n=4), IgG1-N297A (inverted triangles, n=1), IgG1-G236A (open diamonds, n=6) and Afuco-IgG1 (triangles, n=7). Figure 8B : Naive (untreated, black line), IgG1 (dashed line), IgG1-N297A (dotted line), IgG1-G236A (dashed line and dots), and Afuco-IgG1 (dashed line and two dots). Despite rapid tumor progression in naive control mice, all animals previously treated with anti-GITR Abs showed long-term immunity, i.e., rejection of tumors and complete survival in rechallenge. GITR antibodies show potential in mediating long-term anti-tumor T cell memory protection against tumor recurrence.
[0327] To further evaluate the mechanism of long-term protection and memory response of GITR antibodies, experiments were performed in a similar setting as above, but in addition, several tumor-free mice were injected with antibodies against CD4 or CD8. MC38-bearing hFcγR mice and control naive mice treated with anti-GITR Fc region variants, fully responded to previous treatment and became tumor-free were inoculated with MC38 cells, injected with antibodies against CD4 and CD8, and then tumor growth was performed. PBS was used as a control treatment. Over time, the tumor volume of each test animal was tracked. Figures 9A-9D Shown are the results of tumor growth progression in mice injected with aCD4 and aCD8 (dotted lines) and PBS as a control (line) in addition to treatment with anti-GITR Fc region variants. Fig. 9A , control untreated mice. Fig. 9B , IgG1-G236A. Fig. 9C , Afuco-IgG1. Fig.9D , Afuco-IgG1-G236A. Fig.9E The mean tumor volume for each previous Fc region variant treatment is shown: naive (n=6, solid diamonds), IgG1-G236A and PBS (G236A PBS, n=2, open diamonds and black line), IgG1-236A and aCD4 and aCD8 (G236AαCD4+αCD8, n=4, open diamonds and dashed line), Afuco-IgG1 and PBS (defucosylated PBS, n=2, triangles and black line), Afuco-IgGG1 and aCD4 and aCD8 (defucosylated αCD4+αCD8, n=3, triangles and dashed line), Afuco-IgG1-G236A and PBS (n=3, open squares and black line), Afuco-IgG1-G236A and aCD4 and aCD8 (n=4, open squares and dashed line). The survival probability for each previous Fc region variant treatment was calculated and is presented in Fig.9FIn the figure. Original state (dashed line and two dots), IgG1-G236A (line), IgG1-G236AαCD4+αCD8 (dashed line), Afuco-IgG1 (line), Afuco-IgG1 and aCD4 and aCD8 (dotted line), Afuco-IgG1-G236A (line) and Afuco-IgG1-G236A and aCD4 and aCD8 (dashed line and dots). The abundance of CD8+ and CD4+ T cells in peripheral blood was determined by flow cytometry at various time points after antibody administration. For flow cytometric analysis, fluorescently conjugated monoclonal antibodies targeting the β subunit of mouse CD8 (clone YTS156.7.7; Biolegend) or an epitope that does not overlap with the anti-CD4 GK1.5 epitope (clone RM4-4; Thermofisher) were used to avoid competition with the depleting antibody.
[0328] Overall, the tumor growth and overall survival results suggest a T cell-dependent mechanism for long-term tumor immunity mediated by the GITR antibody. Tumor-free mice were re-primed with a second injection of tumor cells and then their T cells were depleted to test T cell dependence on tumor recurrence. The study found that T cells were critical for long-term immunity because in the absence of T cells, tumors expanded and were not rejected.
[0329] Example 4. Defucosylated G236A variant improves the activation / inhibition affinity ratio of the antibody
[0330] The activating receptor FcγRIIA has 90% homology with the inhibitory receptor FcγRIIB (Rankin CT et al., Blood, 2006, supra), so binding to FcγRIIA rather than FcγRIIB is a challenging task. To date, some modifications have been introduced, but most of them have led to enhanced binding to FcγRIIB (DAE variant 18 and GASDALIE, which are disclosed in Smith P et al., Mouse model recapitulating human Fcγreceptor structural and functional diversity, Proc Natl Acad Sci USA, 2012, 109, 6181-6). In the present invention, a new Fc region variant was created by combining two strategies (glycoengineering (defucosylation) and protein engineering by amino acid substitution (G236A)) on the Fc scaffold to produce a defucosylated IgG1-G236A variant. This dual-engineered antibody enhances binding to both FcγRIIA and FcγRIIIA activating receptors and is subsequently able to elicit antibody-mediated effector functions such as dendritic cell activation and phagocytosis, while minimizing binding to the inhibitory FcγRIIB. Figures 10A-10C The binding of aGITR IgG1 (circles), Afuco-IgG1 (diamonds), Afuco-IgG1-G236A (triangles), and IgG1-G236A (squares) to FcγRIIA ( Fig. 10A )、FcγRIIIA( Fig. 10B ) and FcγRIIB (Figure 10c) binding ELISA assay results.
[0331] The novel Afuco-IgG1-G236A variant targeting GITR has improved affinity for both activating Fc receptors relative to the other antibodies tested, while appearing to have lower affinity for the inhibitory FcγRIIB compared to hIgG1 ( Figures 10A-10C ).
[0332] Example 5. Requirements for FcγRIIA and FcγRIIIA for optimal anti-mGITR antibody-mediated anti-tumor immunity
[0333] Since both defucosylated IgG1 and IgG1-G236A resulted in similar enhancement of antitumor activity, further evaluation was performed to establish whether one of these Fc variants was superior to the other and whether they engaged different mechanisms (FcγRIIA vs. FcγRIIIA pathway). Antitumor activity was compared in vivo. Humanized FcγR mice were inoculated with MC38 cells and once tumors reached 115 mm 3 Mice were treated with the indicated chimeric human Fc region variants (containing the anti-mGITR binding domain of the DTA-1 antibody), IgG1-G236A, Afuco-IgG1, and Afuco-IG1-G236A. Tumor progression was monitored for each animal ( Figures 11A-11D ), as the mean tumor volume of each treatment group ( Fig.11E ) and the survival probability ( Fig.11F The Afuco-IgG1-G236A and IgG1 groups were compared using an unpaired two-tailed t-test (n=8 in all groups). The treatment groups were: untreated mice, no tumor-free mice ( Fig.11A ); IgG1-G236A treatment group, 1 / 8 tumor-free mice ( Fig. 11B ); Afuco-IgG1 treatment, 0 / 8 tumor-free mice ( Fig. 11C ); and Afuco-IgG1-G236A treatment, 2 / 8 tumor-free mice ( Fig.11D ). Fig.11E Mean tumor volumes for each treatment group are shown: control untreated mice (untreated, solid diamonds), IgG-G236A (open diamonds), Afuco-IgG1 (triangles), Afuco-IgG1-G236A (squares). Fig.11F The survival probability of mice in each test group is shown: untreated mice (untreated, line), IgG-G236A (dashed line), Afuco-IgG1 (dotted line), Afuco-IgG1-G236A (dashed line and dots).
[0334] As shown in the results, all three Fc region variants still produced significant anti-tumor activity. Mice treated with the Fc region variant Afuco-IgG1-G236A, which exhibits enhanced FcγRIIA and FcγRIIIA, resulted in a significant reduction in tumor growth and a complete response when compared to Afuco-IgG1, but not when compared to the IgG1-G236A variant.
[0335] The novel Afuco-IgG1-G236A demonstrated superior antitumor activity and overall survival in an advanced refractory tumor model compared to the Fc scaffold IgG1 or IgG1-N297A, which are part of an antibody currently in clinical trials. Humanized FcγR mice were inoculated with MC38 cells and once tumors reached 115 mm 3 The average volume of IgG1 was then treated with the indicated human Fc region variants, IgG1-N297A, or Afuco-IgG1-G236A. The mice were followed for tumor progression ( Figures 12A-12D ), mean tumor volume and overall survival probability of each treatment group ( Figures 12E-12F ). Fig.12E Mean tumor volumes for each treatment group are shown: control untreated mice (untreated, solid diamonds), IgG1 (circles), IgG1-N297A (inverted triangles), Afuco-IgG1-G236A (squares). Fig.12F Shown are the survival probabilities of mice in each test group: untreated mice (untreated, line), IgG1 (dashed line), IgG1-N297A (dotted line), and Afuco-IgG1-G236A (dashed line and dots).
[0336] As Fig.12E and 12F As demonstrated in the literature, the double-modified Fc region variant Afuco-IgG1-G236A reduced tumor growth and survival compared to other Fc region variants. An unpaired two-tailed t-test was used to compare Afuco-IgG1-G236A with the IgG1 group. The Fc region variant treatment groups were: untreated mice, no tumor-free mice ( Fig. 12A ); IgG1 treatment, 1 / 9 tumor-free mice ( Fig. 12B ); IgG1-N297A treatment, 0 / 9 tumor-free mice ( Fig. 12C ); Afuco-IgG1-G236A treatment, 5 / 9 tumor-free mice ( Fig.12D ).
[0337] Example 6. Effect of anti-mGITR hIgG on the immune landscape of the tumor microenvironment (TME) and draining lymph nodes (dLN)
[0338] After characterizing the Fc engineered antibody variants, Afuco-IgG1-G236A was found to be a very efficient and suitable human IgG scaffold for GITR mAb, resulting in enhanced anti-tumor activity, and the effects of anti-GITR Fc region variants on TME were evaluated. Humanized FcγR mice with refractory MC38 tumors were treated with 100 μg / mouse / intraperitoneal (IP) injection of anti-mGITR hIgG1Fc region variants Afuco-IgG1-G236A (GA-aFuc), IgG1 Fc silencing N297A (NA), IgG1, and untreated mice were used as controls. Mice were killed and tumors were harvested at three time points after treatment, namely 1 day, 4 days (2 mAb administrations in total), and 8 days (3 mAb administrations in total). To evaluate TME composition, single cell suspensions were generated and the percentage of lymphocytes was analyzed by flow cytometry. Figures 13A-13C The figure shows the flow cytometry results of Treg frequency in the TME of mice 1, 4 and 8 days after anti-GITR Fc region variant treatment, respectively. Treg were detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+. Figures 13D-13F The figure shows the flow cytometry results of the CD8+ cell frequency in the TME of mice 1, 4 and 8 days after the start of anti-GITR Fc region variant treatment, respectively. CD8+ cells were detected by CD45+CD3+CD11b-CD8+CD4-. Figures 13G-13I Figure 3 shows the CD8 / Treg ratio in the TME of mice 1, 4, and 8 days after the start of anti-GITRFc region variant treatment, respectively. Figures 13A-13I : Untreated mice (untreated, diamonds), IgG1 (circles), IgG1-N297A (inverted triangles), and Afuco-IgG1-G236A (squares). Unpaired two-tailed t-test was used. Data are expressed as mean ± SEM.
[0339] As can be seen from Figures 13A-13IAs can be seen, Treg frequencies were significantly reduced after treatment with all Fc region variants, except for the IgG1 Fc-silenced N297A (NA), indicating Fc-mediated depletion of intratumoral Tregs. Using the Fc-enhanced variant Afuco-IgG1-G236A (GA-aFuc), the reduction in Treg frequency occurred at an early time point (1 day), while CD8+ T cell frequencies remained the same at this early time point. Nevertheless, at later time points (8 days), an increase in CD8+ T cell frequencies was observed with the Fc-enhanced variants, but not with IgG1. GA-aFuc exhibited the highest CD8 / Treg ratio at an early time point (4 days), while the other variants did so at later time points. Only GA-aFuc treatment showed a significant increase in the CD8 / Treg ratio at early time points compared to IgG1-N297A, while at later time points, increases were also observed between IgG1 Fc region variants compared to IgG1-N297A.
[0340] The activation status of DCs within the TME and dLN was assessed by measuring DCs and activation markers in the TME and dLN of humanized FcγR mice inoculated with MC38 cells and treated with human anti-GITR Fc region variants Afuco-IgG1-G236A (GA-aFuc), IgG1 Fc silencing N297A (NA), and IgG1. Tumors and dLNs from untreated mice served as controls. Tumors and dLNs were harvested 4 and 8 days after the start of mAb treatment, and single cell suspensions were then generated from the harvested organs and analyzed by flow cytometry. Figures 14A-14F Flow cytometry for detecting DCs in the TME (14A-14C) and dLN (14D-14F) and activated DCs after 4 days of treatment with Afuco-IgG1-G236A (GA-aFuc, inverted triangles), IgG1 Fc-silenced N297A (IgG1-N297A, triangles), and IgG1 (squares). Untreated mice served as controls (untreated, circles). Fig.14A The percentage of DCs in the TME detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+ is shown. Fig. 14B Shown are the geometric mean fluorescence intensity (gMFI) of activated CD80 DC in the TME detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+. Fig. 14C Shown are the gMFI of activated CD86 DCs in the TME detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+. Fig.14D Shows Fig.14A The percentage of DCs in the dLNs examined. Fig.14E Shows Fig. 14B Geometric mean fluorescence intensity (gMFI) of activated CD80 DCs in the assayed dLN. Fig.14F Shows Fig. 14C gMFI of activated CD86 DCs in dLN as measured above. Figure 14G The percentage of DC in the TME of mice treated as described in Figure 14 is shown 8 days after the start of treatment. Geometric mean fluorescence intensity (gMFI) was calculated using FLOWJO software. A common one-way ANOVA with Tukey's multiple comparison statistical test was used. Data are expressed as mean ± SEM.
[0341] As can be seen from Figures 14A-14G As can be seen, the percentage of DCs in the TME decreased between days 4 and 8 after the start of treatment ( Fig.14A and 14G Compared with the results observed with the IgG1 variant, an increase in the percentage of DCs was observed in dLN 4 days after the start of treatment ( Fig.14D Although all Fc region variants except the IgG1 Fc-silenced N297A (NA) also exhibited an increase in the density of CD80 or CD86 activation markers within the TME and dLN (14B-14C and 14E-14F), the Afuco-IgG1-G236A (GA-aFuc) variant exhibited the highest increase in both markers.
[0342] Example 7. Effect of anti-human GITR hIgG on the immune landscape of the tumor microenvironment (TME) and draining lymph nodes (dLN)
[0343] To test whether the optimized Fc region variant (Afuco-IgG1-G236A) maintains its enhanced anti-tumor activity while targeting hGITR, the heavy and light chains of the anti-hGITR humanized antibody TRX518 were synthesized and cloned into a mammalian expression vector to form an anti-hGITR humanized antibody. G236A and N297A mutations were introduced into the CH2 domain by site-directed mutagenesis to generate Afuco-IgG1-G236A Fc region variants of TRX518 (N297A) and the same GITR mAb clone with enhanced binding to activating hFcγR. The amino acid sequence of the heavy chain constant region of the Afuco-IgG1-G236A variant, in which alanine at position 236 is substituted for glycine, is set forth in SEQ ID NO: 13. This variant and the light chain constant region of TRX518 conform to SEQ ID NO: 14.
[0344] Following production, the binding affinity of the anti-hGITR (anti-hGITR) Fc region variants was measured and validated by comparative ELISA, where OD450 values were plotted against increasing concentrations of the test antibody to assess binding of plate-bound proteins. Fig.15A ELISA results of humanized test antibody IgG1 (circle), hGITR TRX518 (TRX518 (IgG1-N297A), inverted triangle), Afuco-IgG1-G236A (square) binding to hGITR are shown. The binding affinity of the Fc region variants to hFcγR members RIIA and RIIIA was also measured by ELISA. 15B-15C show the ELISA results of test antibody IgG1 (circle), hGITR TRX518 (TRX518 (IgG1-N297A), inverted triangle), Afuco-IgG1-G236A (square) binding to FcγRIIA and FcγRIIIA, respectively.
[0345] Fig.15A The results depicted in Figure 4 show that different Fc scaffolds of anti-hGITR TRX518 retain binding affinity to hGITR with comparable binding affinities. TRX518 (IgG1-N297A, triangles) clearly lacks binding to both human FcγRs, while "Afuco-IgG1-G236A" (squares) exhibits increased binding to both human FcγRIIA and FcγRIIIA.
[0346] Example 8. Regulation of FcγR-dependent tumor infiltrating lymphocytes (TILs) after anti-GITR treatment
[0347] To evaluate the effects of humanized anti-hGITR Fc region variants on immune cell regulation in the blood and within the TME, FcγR and GITR humanized mice (hFcγR / hGITR) were generated.
[0348] Humanized FcγR / hGITR mice bearing refractory MC38 tumors were treated with anti-hGITR antibody TRX518 (IgG1-N297A) and its Fc region variant Afuco-IgG1-G236A. Treg levels in the blood were assessed over time after a single administration of the anti-hGITR Fc region variants. Fig.16Results of blood Treg frequencies after treatment with anti-hGITR antibody TRX518 (IgG1-N297A, inverted triangles), Afuco-IgG1-G236A (squares) are shown, with untreated mice as controls (untreated, diamonds). Blood Treg frequencies similarly decreased 22 hours after treatment with both Fc-silencing IgG1-N297A (triangles) and Afuco-IgG1-G236A (squares) variants, but Treg frequencies decreased at an earlier time point (2 hours) after treatment with Afuco-IgG1-G236A compared to treatment with IgG1 Fc-silencing N297A. Four days after the start of treatment, Treg levels in the blood recovered.
[0349] Next, we assessed TME composition by harvesting tumors 4 days after treatment initiation (after 2 antibody administrations), preparing single-cell suspensions, and analyzing the regulation of immune compartments in the TME by flow cytometry. Figures 17A-17C Flow cytometry showing the effect of different Ab variants on the percentage of CD4+FoxP3, CD8+, and Treg in the TME, respectively. TRX518-IgG1-N297A (TRX518(IgG1-N2971), inverted triangles) or Afuco-IgG1-G236A (squares), untreated mice served as controls (untreated, diamonds). Unlike TRX518-IgG1-N297A depletion of Tregs in the blood and huFcγR / GITR in vivo models described above, Treg depletion within the TME was limited to the Afuco-IgG1-G236A treatment group ( Fig. 17C ), while no changes were observed in other TILs ( Fig.17A -B). In contrast to the Fc-silencing antibody TRX518 currently in clinical trials, anti-hGITR-mediated Treg depletion was found to be FcγR-dependent.
[0350] Example 9. Treg depletion by the anti-GITR Afuco-IgG1-G236A variant is NK-independent
[0351] For in vivo NK depletion assay, humanized FcγR mice challenged with refractory MC38 tumors were treated twice (day 0 and day 3) with 100 μg / mouse / IP injection of anti-mGITR hIgG1 Fc region variant Afuco-IgG1-G236A (GA-aFuc) and IgG1 Fc silencing N297A (NA), while NK cells were depleted. Humanized FcγR mice were challenged with refractory MC38 tumor cells 14 days before the first treatment with anti-mGITR hIgG1 Fc region variant (day 0) (day -14). NK cell depletion was performed with αNK1.1 (250ug, #BE0036, BioXCell) 1 day and 2 days before and after the first treatment with anti-mGITR hIgG1 Fc region variant (days -2, -1, 1 and 2). NK cell loss was verified on days 0 and 4. Mice treated with PBS or PBS and αNK1.1 were used as controls. Blood was drawn from the test animals on days 0 and 4 after the start of anti-mGITR hIgG1 Fc region variant treatment and analyzed by flow cytometry for the presence of NK cells. In addition, single cell suspensions generated from tumors harvested on day 4 after the start of treatment were analyzed by flow cytometry to investigate regulation in the immune compartment in the TME.
[0352] Fig.18A Shown is a timeline from inoculation of refractory MC38 tumor cells into mice to initiation of anti-mGITR hIgGl Fc region variant treatment on day 4, when blood was drawn and tumors harvested. Figures 18B-18C Flow cytometry of NK cells in mouse blood samples at day 0 and day 4 after initiation of anti-mGITRhIgG1 Fc region variant treatment and NK cell depletion, respectively, is shown. NK cells were detected using CD45+CD3-NKp46+, and blood from mice treated with PBS alone was used as a negative control. Figures 18D-18FThe cell counts per mg tumor of NK cells (detected by CD45+CD3-NKp46+), Treg cells (detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+) and CD8+ cells (detected by CD45+CD3+CD11b-CD8+CD4-) are shown respectively. Mice treated with PBS (PBS, filled circles), mice treated with PBS and αNK1.1 (PBS+αNK1.1, open circles), IgG1-N297A (filled squares), IgG1-N297A and αNK1.1 (IgG1-N297A+αNK1.1, open squares), Afuco-IgG1-G236A (filled triangles), Afuco-IgG1-G236A and αNK1.1 (Afuco-IgG1-G236A+αNK1.1, open triangles). Unpaired two-tailed t-test was used. Data are expressed as mean ± SEM.
[0353] As can be seen from Figures 18B-18C As can be seen, significant NK cell depletion was achieved in mice injected with αNK1.1 as early as day 0 from the start of anti-mGITR hIgG1 Fc region variant treatment, compared to negative control mice injected with PBS alone. Between day 0 and day 4 from the start of anti-mGITR hIgG1 Fc region variant treatment, NK cell depletion was even more extensive in mice injected with αNK1.1. Figures 18D-18F As can be seen, the absolute number of intratumoral NK cells showed depletion in all groups injected with αNK1.1 compared to control mice injected with PBS. In the afuco-IgG1-G236A (GA-aFuc)-treated group, Treg cells were depleted in a manner independent of NK cells, and a much more moderate depletion of Tregs was observed in the IgG1 Fc-silenced N297A (NA)-treated group. In groups of mice treated with afuco-IgG1-G236A (GA-aFuc) or IgG1 Fc-silenced N297A (NA), CD8+ cell levels remained unchanged 4 days after the start of treatment. In vivo NK depletion assays indicate that Treg depletion is independent of the presence of NK.
[0354] Example 10. Generation and characterization of non-agonistic bispecific Afuco-IgG1-G236A anti-GITR antibody
[0355] To evaluate the necessity of bivalent GITR agonism in tandem with enhanced FcγR targeting, non-agonistic bispecific antibodies were generated using conventional methods based on the Fc scaffolds of Afuco-IgG1-G236A and IgG1-N297A and the Fab of the humanized anti-RSV (respiratory syncytial virus) antibody Synagis (palivizumab). The Afuco-IgG1-G236A Fc scaffold and Synagis Fab were used to generate the GITR / Synagsis Afuco-IgG1-G236A bispecific antibody, and IgG1-N297A and Synagis Fab were used to generate the GITR / NA Synagis bispecific antibody. The new bispecific antibodies were purified and characterized by ELISA, high performance liquid chromatography (HPLC) and mass spectrometry. For HPLC, samples of the two bispecific non-agonistic Abs were digested with trypsin using the S-trap method. The resulting peptides were analyzed using nanoflow liquid chromatography (nanoAcquity) coupled to a high-resolution, high-quality precision mass spectrometer (Exploris). Each sample was analyzed independently in random order on the instrument in discovery mode. Data was processed for IgG1 peptides and Fc glycan libraries using the Byonic search engine. Data were quantified and manually verified using Skyline. The binding of the bispecific antibody to FcγR (FcγRIIA, FcγRIIB and FcγRIIIA) was measured. The OD450 values obtained in the ELISA assay were plotted against the increased concentrations of the indicated antibodies to assess the binding of the protein bound to the plate. Monospecific afuco-IgG1-G236A was used as a control. Figures 19A-19C ELISA results of the binding of the bispecific non-agonist variants Afuco-IgG1-G236A (circles), GITR / Afuco-IgG1-G236ASyn (DTA1 / Syn GA-aFuc, triangles) and GITR / NA Syn (DTA1 / Syn, inverted triangles) to different hFcγRs (FcγRIIA, FcγRIIB and FcγRIIIA) are shown, respectively. The monospecific Afuco-IgG1-G236A (DTA1 GA-aFuc) was used as a control (circles). Fig.19D HPLC analysis of trypsin-digested GITR / Afuco-IgG1-G236A Synagis non-agonistic antibody is shown. Data are presented as mean ± SEM.
[0356] As can be seen from Figures 19A-19DAs can be seen, GITR / Afuco-IgG1-G236A Synagis humanized bivalent (bispecific) and monovalent Afuco-IgG1-G236A (monospecific) antibodies have similar binding abilities to different hFcRs. However, GITR / Afuco-IgG1-G236A Synagis showed that the Fc domain preferentially binds to activating Fc receptors. HPLC analysis showed that the protein purity was 80%. In addition, mass spectrometry analysis showed that the yield of the non-fucosylated form of GITR / Afuco-IgG1-G236A Synagis was ˜73.13%. The bispecific anti-mouse GITR / Synagis was produced with high purity, and both the Fab and Fc domains had the desired binding properties.
[0357] Example 11. In vitro activity assay of anti-mouse GITR / Synagis bispecific mAb
[0358] Produced anti-mouse GITR (mGITR) non-agonist bispecific mAb with N297A substitution in Fc, named mGITR / NA Synagis. The ability of novel mGITR / NA Synagis to bind mGITR was assessed by ELISA and compared with monospecific mIgG1-N297A. Optical density 450 (OD450) values were plotted for the increased concentrations of mGITR / NA Synagis and mIgG1-N297A to assess the binding of plate-bound proteins. Next, isolated T cells from WT mice were incubated with anti-CD3 antibodies and anti-mGITR / NA Synagis or monospecific mIgG1-N297A with increased concentrations. Non-GITR binding antibodies with N297A substitution in the Fc region served as isotype controls. 24 hours after incubation, supernatants were subjected to ELISA to detect mouse IL-2 secreted by T cells. IL-2 ELISA was performed using Biolegened ELISA MAXTM Deluxe Kit Mouse IL-2 (BLG-431004) according to the manufacturer's instructions. Data are expressed as mean ± SEM. Fig. 20A The mGITR binding capacity of the novel mGITR / NA Synagis (squares) compared to the monospecific mIgG1-N297A (solid circles) is shown. Fig. 20BShown are murine IL-2 (mIL-2) secretion (pg / ml) of T cells (activated with anti-CD3 antibodies) after incubation with increasing concentrations of anti-mGITR / NASynagis (squares), monospecific mIgG1-N297A (filled circles) or a non-GITR binding antibody with N297A substitution in the Fc region (isotype control NA) as an isotype control (isotype control NA, triangles). The dotted line indicates the natural threshold of IL-2 concentration after activation with anti-CD3 antibodies and without any Ab treatment.
[0359] As can be seen in Figures 20A-20B As can be seen in Figure 2, the bispecific mGITR / NA Synagis has lower binding capacity to mGITR compared to the monospecific mIgG1-N297A. -3 At an antibody concentration of 10 μg / ml, the OD450 of mGITR / NA Synagis was already significantly lower (0.18) compared to mIgG1-N297A (0.6). mIgG1-N297A reached a saturation point at ~10-1.5 μg / ml, with a plateau having an OD450 value of ~0.9, while mGITR / NA Synagis reached the same OD value and plateau at an antibody concentration of ~100 μg / ml. This difference is consistent with the valency of the antibodies, with each bispecific mGITR / NA Synagis antibody only able to bind one mGITR molecule, while each monospecific mIgG1-N297A antibody was able to bind two mGITR molecules.
[0360] mGITR / NA Synagis did not elicit mIL-2 secretion from anti-CD3 antibody-activated murine T cells at increasing concentrations. T cells incubated with mGITR / NA Synagis secreted even lower levels of mIL-2 than a non-GITR-binding isotype control antibody. The lack of ability of mGITR / NA Synagis to elicit IL-2 secretion from T cells indicates a lack of agonistic activity. However, at ~10 -3 to 10 -1.5 Incubation with mIgG1-N297A at antibody concentrations between 10 μg / ml and 20 μg / ml elicited mIL-2 secretion from anti-CD3 antibody-activated murine T cells in a dose-dependent manner, where the secretion level remained the same despite increasing concentrations of mIgG1-N297A. -3 to 10 1.5 mIgG1-N297A exhibited agonist activity by binding to mGITR in a dose-dependent manner and secretion of IL-2 by activated T cells at a concentration range of μg / ml.The bispecific technology enables the generation of non-agonist anti-GITR antibodies.
[0361] Example 12. Anti-GITR variants GA-aFuc and bispecific non-agonistic humanized afuco-IgG1 exhibit in vivo anti-tumor activity
[0362] Humanized FcγR mice were stimulated with refractory MC38 tumors. 14 days after stimulation, mice were treated with 100 μg mouse anti-DTA-1 (anti-GITR) GA-aFuc Ab or 100 μg, 200 μg or 400 μg of humanized GA-aFuc Fc region variant (GITR / syn GA-aFuc) Ab of non-agonistic bispecific antibodies. Untreated mice served as negative controls. Tumors were harvested 24 hr after treatment, single cell suspensions were prepared, and the regulation of Treg in TME was analyzed by flow cytometry. Fig.21 Flow cytometry analysis of the percentage of Treg in the TME after treatment with 100 μg (square), 200 μg (triangle) or 400 μg (diamond) GITR / syn GA-aFuc and 100 μg GA-aFuc (inverted triangle) is shown. Untreated mice served as the control group (untreated, circle). Tumors from untreated mice and negative controls were analyzed. Tregs were detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+. Data are expressed as mean ± SEM. (n=5 mice / group, one-way ANOVA).
[0363] As can be seen from Fig.21 As seen, both non-agonistic and agonistic aGITR antibodies showed a significant ability to immunomodulate the TME via in vivo Treg depletion. The reduction in the percentage of Tregs in the TME correlated with the concentration of the novel non-agonistic GITR / syn GA-aFuc.
[0364] Example 13. Agonistic and non-agonistic humanized afuco-IgG1 GA variants exhibit anti-tumor activity in vivo
[0365] To further evaluate the in vivo anticancer immunity of GITR / syn-GA-Fuc and GA-aFuc, hFcγR mice bearing refractory MC38 tumors were treated with GA-aFuc Ab or non-agonistic GITR / syn GA-aFuc Ab 14 days after tumor cell inoculation, and tumor progression (tumor volume) was monitored for 20 days. Untreated mice served as controls and were sacrificed on day 13 to prevent the animals from further suffering. Figures 22A-22C Shown are tumor volumes (mm) in hFcγR mice bearing MC38 tumors after treatment with 100 μg GA-aFuc Ab (solid triangles) or 200 μg non-agonistic GITR / syn GA-aFuc Ab (open triangles). 3) The results of the progression. Untreated mice served as controls (solid circles), n=9 for each test group. Fig.22A Tumor volume measurements at day 20 are shown. Fig. 22B Shown are the tumor volumes of mice in all groups on day 13 after the start of treatment. Fig. 22C Tumor volumes of mice in the GA-aFuc Ab and GITR / syn GA-aFuc Ab test groups are shown on day 15 after the start of treatment. Untreated mice were sacrificed on day 13 and are not shown in this figure.
[0366] from Figures 22A-22C It can be clearly seen that both non-agonistic aGITR Abs (GITR / syn GA-aFuc and GA-aFuc) showed successful anti-tumor efficacy in vivo. However, non-agonistic GITR / syn GA-Fuc showed significantly higher cancer immunity compared to the agonistic aGITR antibody GA-aFuc. Therefore, the non-agonist aGITR variants showed an enhanced ability to inhibit tumor growth in vivo compared to the matched Fc agonistic aGITR mAb.
[0367] Example 14. In vivo dendritic cell activation of agonistic and non-agonistic humanized afuco-IgG1 GA variants
[0368] Humanized FcγR mice were inoculated with refractory MC38 tumors. At 0 and 3 days after the start of treatment, the mice were treated twice with 100 μg GA-aFuc Ab or 200 μg GITR / syn GA-aFuc Ab. Untreated mice were used as negative controls. Tumors were harvested 24 hr after the second treatment, single cell suspensions were prepared, and TME, i.e., Treg depletion and dendritic cell (DC) activation, was analyzed by flow cytometry. Figures 23A-23B Flow cytometry analysis of the percentage of Treg and DC in the TME after treatment with 200 μg GITR / syn GA-aFuc (GITR / synAfuco-IgG1-G236A, inverted hollow triangles) and 100 μg GA-aFuc (Afuco-IgG1-G236A, inverted solid triangles) is shown respectively. Tumors from untreated mice and negative controls (circles) were analyzed. Tregs were detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+, and DCs were detected by CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+. Data are expressed as mean ± SEM. (n=5 mice / group, one-way ANOVA). Figures 23C-23DFlow cytometric analysis of DC activation by detecting the percentage of DC expressing CD80+ or CD86+ is shown respectively. GITR / syn Afuco-IgG1-G236A (inverted hollow triangles), Afuco-IgG1-G236A (inverted solid triangles), tumors from untreated mice, and negative controls (circles) were analyzed. The geometric mean (gMFI) of fluorescence intensity was calculated using FLOWJO software. DC was detected by CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+, CD80+DC was detected by adding anti-CD80 antibodies, and CD86+DC was detected by adding anti-CD86 antibodies. Data are expressed as mean ± SEM, and each point represents one mouse (n = 5 mice / group, one-way ANOVA).
[0369] Figures 23A-23B The results showed that Tregs underwent significant depletion, but DC levels were stable after treatment with either aGITR Ab (GITR / syn GA-aFuc and GA-aFuc) compared with control mice, indicating that the agonistic and / or non-agonistic activities of aGITR Ab do not affect or regulate the levels of DCs.
[0370] Figures 23C-23D The results showed that treatment with GITR / syn GA-aFuc or GA-aFuc Ab significantly increased CD80+DC. Treatment with GITR / syn GA-aFuc Ab significantly increased the level of CD86+DC, and the increase in CD86+DC after treatment with GA-aFuc Ab was smaller. Both GITR / syn GA-aFuc or GA-aFuc Ab showed Fc region-mediated DC activation.
[0371] Example 15. In vivo anticancer activity of mouse aGITR-mIgG2a variants in wild-type mice
[0372] The anticancer activity of anti-GITR-mIgG2a Abs with preferential binding to the activating murine receptors FcγRI and FcγRIV was evaluated. Wild-type (WT) C57BL / 6J mice with MC38 tumors were treated with 100 μg of mouse anti-GITR (DTA-1) Ab (DTA-1mIgG2a) or 100 μg of mIgG2a-N297A Ab (DTA-1mIgG2a NA) with silent mutation N297A in the Fc region of mIgG2a, which is a parallel mouse Fc with activating Fc receptor enhancement, 8 days after tumor cell inoculation. Tumor progression was monitored for 17 days by measuring tumor volume. Untreated mice were used as controls.
[0373] Fig.24AShown are the results of 17-day monitoring of tumor volume progression in WT mice bearing MC38 tumors after treatment with 100 μg DTA-1mIgG2a (squares) or 100 μg DTA-1mIgG2a NA Ab (triangles). Untreated mice served as controls (solid circles). Data are expressed as mean ± SEM, n = 9 mice / group.
[0374] As can be seen from Fig.24A As seen, mice treated with 100 μg of Fc-bound DTA-1 mIgG2a Ab showed a statistically significant reduction in tumor growth and a complete response compared to mIgG2a-N297A.
[0375] Next, WT mice with MC38 tumors were treated with 100 μg DTA-1mIgG2a Ab and 100 μg DTA-1mIgG2a NA, while untreated mice were used as negative controls. Tumors were harvested 4 days after treatment, single cell suspensions were prepared, and the regulation in the immune compartment in TME was analyzed by flow cytometry. The immunomodulatory parameters measured were Treg counts / mg tumor (detected using anti-FoxP3 antibodies) and DC percentage of total lymphocytes (detected using anti-CD11c / anti-CD45 antibodies), DC activation status (detected using anti-CD80 or anti-CD86 antibodies). Figures 24B-24E Flow cytometry analysis of the parameters detailed above in harvested tumors of WT mice treated with 100 μg DTA-1mIgG2a Ab (mIgG2a, squares) and 100 μg of DTA-1mIgG2a NA (mIgG2a-N297A, triangles) or untreated mice used as controls (PBS, circles) is shown. Each point represents a mouse, n=6 mice / group, data are expressed as mean ± SEM, and analyzed using one-way ANOVA. ΔgMFI was calculated using FLOWJO software. Unpaired t-test was used. Fig. 24B Shown are Treg counts / mg tumor detected using anti-FoxP3 antibody in all tested groups. Fig.24C Shown are the percentages of DCs to total lymphocytes (detected using anti-CD11c / anti-CD45 antibodies) in all tested groups. Fig.24D The ΔgMFI of CD80+ activated DCs in all tested groups is shown. Fig.24E The ΔgMFI of CD86+ activated DCs in all tested groups is shown.
[0376] As it can be done Figures 24B-24EAs seen, both DTA-1mIgG2a and DTA-1mIgG2aNA induce significant Treg depletion in vivo compared to untreated mice. In addition, DTA-1mIgG2aAb induces significantly greater Treg depletion compared to the Fc-ineffective antibody mIgG2a NA, indicating that the specificity of the Ab and Fc interactions contribute to the immunomodulatory ability of the Ab. In vivo treatment with DTA-1mIgG2a Ab modulates TME immune cell populations, significantly increasing the percentage of DCs compared to DTA-1mIgH2aNA, indicating that Fc interactions are essential for the increase of DCs in the TME. In addition, in vivo treatment with DTA-1mIgG2a Ab significantly increased the activation of DCs compared to both untreated mice and DTA-1mIgG2a NA, which is reflected in the number of CD80+ and CD86+ activated DCs in the TME. Strikingly, in the case of CD80+ activated DCs, the increase in this DC population by DTA-1mIgH2a Ab compared to DTA-1mIgR2a NA was even greater than the increase compared to untreated mice. In conclusion, DTA-1mIgG2a was shown to have an enhanced anti-tumor response, enhanced Treg reduction, increased the percentage of DCs in the TME, and elevated DC activation markers CD86 and CD80 compared to Fc null antibodies.
[0377] This Fc-binding antibody, DTA-1mIgG2a, was further evaluated in various DC knockout (KO) mouse models to determine the dependence of anti-GITR antitumor efficacy on the presence of DCs.
[0378] Example 16. In vivo anticancer activity of mouse aGITR-mIgG2a variant in BATF3- / - mouse model
[0379] cDC1 cells are a subset of DCs that are very efficient in presenting cell-associated antigens bound to class I MHC molecules (MHC-I). This property of cDC1 cells contributes to their major role in CD8+ T cell priming, particularly against infected or tumor cells. BATF3- / - mice bearing MC38 tumors that lack only the DC subset cDC1 cells were treated with DTA-1mIgG2a Ab or DTA-1mIgG2a-NA Ab 9 days after inoculation. Tumor volume (mm 3 ) progressed for 13 days. Untreated mice served as negative controls and were sacrificed on day 10 after treatment to avoid unnecessary suffering of the animals. Fig.25Shown are BATF3 in MC38 tumors treated with 100 μg DTA-1mIgG2a (mIgG2a, squares) Ab and 100 μg DTA-1mIgG2a-NA Ab (mIgG2aNA, triangles). - / - Tumor volume (mm) at day 13 in mice treated with PBS or untreated mice used as controls (PBS, circles). 3 ) The results of the progress. Data are expressed as mean ± SEM, n = 8, unpaired t test.
[0380] Fig.25 It was shown that in the first 6 days after treatment, tumor progression in all groups was essentially the same. From the 6th to the 9th day after treatment, the tumor growth rate of mice treated with the Fc-bound Ab DTA-1mIgG2a began to decline, while the tumor growth rate in the other groups remained essentially unchanged. From the 10th day after treatment, mice treated with DTA-1mIgG2a Ab showed a statistically significant reduction in tumor growth compared to mIgG2a-N297A and untreated mice. Without wishing to be bound by any theory or mechanism of action, the results indicate that the lack of cDC1 cells hinders the efficacy of the Fc-ineffective aGITR Ab DTA-1mIgG2a NA Ab, rendering it ineffective, which may be due to insufficient T cell priming and subsequent lack of agonist action. The delayed effect of DTA-1mIgG2a Ab (detected only from the 10th day after treatment) may be due to its retention of Treg depletion activity, but lack of agonism on effector cells.
[0381] Example 17. In vivo anticancer activity of mouse aGITR-mIgG2a variants in XCR1-iDTR and ZBTB46-iDTR mouse models
[0382] The XCR1-iDTR and ZBTB46-iDTR mouse models are models in which DCs can be transiently depleted through the DT receptor (DTR) after injection of diphtheria toxin (DT). XCR1-iDTR is an inducible cDC1 cell depletion model, while ZBTB46-iDTR is an inducible cDC1 and cDC2 cell depletion model. As previously mentioned, cDC2 cells are particularly efficient in eliciting CD4+T cells and cDC1 cells, promoting CD8+T cell elicitation. XCR1-iDTR and ZBTB46-iDTR mice with MC38 tumors were treated with 100μg DTA-1mIgG2a Ab, 20ng / gr body weight of DT, or a combination of 100μg DTA-1mIgG2a Ab and DT 20ng / gr body weight. DT was injected at a dose of 20ng / g every other day to deplete DCs. Tumor volume progression was monitored for 13 days (XCR1-iDTR mice) or 20 days (ZBTB46-iDTR mice). Figures 26A-26B Figure 2 shows tumor volumes (mm) in XCR1-iDTR and ZBTB46-iDTR mice treated with 100 μg DTA-1mIgG2a Ab (mIgG2a, filled squares), 20 ng / gr bw DT (DTx, circles), or a combination of 100 μg DTA-1mIgG2a Ab and 20 ng / gr bw DT (mIgG2a+DTx, open squares), respectively. 3 ) Results of the progression. Untreated mice were used as controls (untreated, circles), n=5-10 mice / group for XCR1-iDTR assay, n=8 mice / group for ZBTB46-iDTR assay. Data are presented as mean±SEM, unpaired t-test.
[0383] As can be seen in Fig.26A As seen in Figure 2, a similar trend to that of the BATF3- / - mouse model assay was observed in the XCR1-iDTR mouse model, with a delayed effect of DTA-1mIgG2a Ab on tumor growth reduction in mice treated with DTA-1mIgG2a Ab compared to mice treated with the combination of DTA-1mIgG2a Ab and DT. In the XCR1-iDTR assay, the effect of the mIgG2a antibody was abrogated after DT administration, further indicating that DCs, particularly cDC1, are necessary for mediating the successful antitumor activity of the Fc-bound DTA-1 antibody.
[0384] As can be seen in Fig.26BAs seen in Figure 2, in the ZBTB46-iDTR model, both cDC1 and cDC2 cell populations were depleted, and the efficacy of Fc-bound DTA-1mIgG2a Ab was abolished after cDC depletion by DT. However, treatment with DTA-1mIgG2a Ab alone showed a dramatic and significantly lower tumor volume progression compared to treatment with a combination of DTA-1mIgG2a Ab and DT. Treatment with DTA-1mIgG2a Ab alone even stopped tumor growth from the early stage on day 3 after treatment.
[0385] Without wishing to be bound by any theory or mechanism of action, the Fc-bound DTA-1 antibody requires binding to DCs to mediate the enhanced anti-tumor effect observed. In the absence of these cells in the system, it loses its potency due to unwanted binding to other effector cells in the environment, and may even have its effects neutralized to that of the untreated group.
[0386] Example 18. Effect of aGITR on Treg depletion-mediated DC activation in vivo
[0387] The in vivo effects of anti-GITR Ab on Treg depletion-mediated DC activation were compared with the effects of anti-CD25 antibodies, a Treg depletion antibody known in the art. To this end, tumors and dLNs were harvested from C57BL / 6J mice with refractory MC38 treated with 100 μg anti-mouse GITR mIgG2a or 100 μg anti-CD25 antibodies 4 days after treatment. Single cell suspensions were generated from harvested organs and analyzed by flow cytometry for Treg regulation in immune compartments in the TME and dLN or DC activation in the dLN. Untreated mice served as controls. Figures 27A-27B The percentage of Treg in the TME and the percentage of DC in dLN of mice treated with 100 μg mouse anti-GITR Ab (aGITR (DTA-1) , squares), 100 μg anti-CD25 Ab (aCD25, triangles) or untreated mice (untreated, circles) are shown, respectively. Tregs are detected by CD45+CD3+CD11b-CD8-CD4+FoxP3+, and DCs are detected by CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+. Each point represents an individual mouse, n=5 / 6 mice / group. Data are shown as mean ± SEM and analyzed using one-way ANOVA. Figures 27C-27DCD80+ and CD86+ activated DCs in dLNs of mice treated with 100 μg mouse anti-GITR Ab (aGITR (DTA-1) , squares), 100 μg mouse anti-CD25 Ab (aCD25 , triangles), or untreated mice (untreated , circles) are shown, respectively. Activated CD80+ DCs were detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+CD80+, and activated CD86 DCs were detected with CD45+CD11b-NK1.1-F4 / 80-CD11c+MHCII+CD86+. Each point represents an individual mouse, n=5 / 6 mice / group. ΔgMFI was calculated using FLOWJO software. Data are shown as mean ± SEM and analyzed using one-way ANOV.
[0388] Figures 27A-27B The results showed that compared with untreated mice, there was a significant and almost complete depletion of Tregs in the TME in both anti-GITR AB and anti-CD25 antibody treated mice. Anti-GITR AB showed a significant increase in the percentage of DCs in dLN compared with anti-CD25 antibody and untreated mice. The percentage of DCs in untreated mice and anti-CD25 antibody treated mice was similar.
[0389] Figures 27C-27D It was shown that anti-GITR Ab triggered a significant activation of CD80+ compared to untreated mice, and significantly increased compared to anti-CD25 Ab. In addition, anti-GITR Ab triggered a significant activation of CD86+ DCs compared to anti-CD25 Ab, and the increase was even higher compared to untreated mice.
[0390] Since both anti-GITR and anti-CD25 antibody treatment mediated almost complete depletion of Tregs, but only anti-GITR antibody showed an increase in DCs and triggered their activation, it was shown that DC activation mediated by Treg depletion in vivo is GITR-dependent.
[0391] Example 19. FcγRIIA and FcγRIIIA requirements for optimal anti-mGITR antibody-mediated anti-tumor immunity
[0392] Humanized FcγR mice were inoculated with MC38 cells once tumors reached 55 mm 3 The mice were treated with chimeric human Fc region variants. Tumor-bearing mice were treated with IgG1-N297A or IgG1-GAALIE every 3 days for a total of 3 treatments (100 μg / mouse per treatment). Tumor progression was monitored for each animal as the average tumor volume for each treatment group. Figures 28A-28CTumor volume progression in mice treated with IgG1-N297A (N297A) or IgG1 GAALIE (GAALIE) is shown, untreated mice served as controls (untreated). Each line represents one animal. Fig.28D Results showing the mean tumor volume of each treatment group IgG1-N297A (N297A, n=8), IgG1-GAALIE (GAALIE, n=9), control untreated mice (untreated, n=8). Unpaired two-tailed t-test was used to compare the IgG1-N297A and IgG1-GAALIE groups. Data are expressed as mean ± SEM.
[0393] As can be seen from Figures 28A-28D As can be seen, by day 8 post-treatment, mice treated with IgG1-GAALIE had significantly reduced tumor volume, while mice treated with IgG1-N297A showed increased tumor volume. As demonstrated in Example 5, GAALIE showed enhanced FcγRIIa and FcγRIIIa compared to IgG1-N297A, reflecting a statistically significant reduction in tumor growth. IgG1 GAALIE showed excellent anti-tumor activity.
[0394] Example 20. In vivo comparison of anti-tumor immunity of aGITR variants in mice bearing MC38 and B16F10 cancer
[0395] hFcγR mice were inoculated with MC38 or B16F10 cells and treated with human Fc region variants of DTA-1 (anti-mouse GITR antibody): IgG1-N297A, GAALIE, IgG1, and GA-aFuc. The mice were monitored for tumor volume progression and overall survival. Next, single-cell multi-omics was used to map the tumor immune profile after treatment, which enables parallel single-cell genome and transcriptome amplification and multi-level analysis based on single-cell data.
[0396] Example 21. Generation of animal models for evaluating binding and activity of anti-hGITR antibodies
[0397] Humanized GITR / FcγR, GITR Tg mice are generated using two different approaches, namely genetic engineering and more traditional breeding. For the genetic engineering approach, human bacterial artificial chromosome clones (BACs) containing the GITR gene and its associated gene expression genomic regulatory elements are being evaluated. For the breeding approach, the above humanized FcγR mice are bred with hGITR knock-in mice in which mouse GITR is replaced by human sequences. The binding and activity of anti-hGITR antibodies are evaluated in vivo using, for example, two commercially available humanized GITR mice, Biocytogen and GenOway.
[0398] Example 22. In vitro anti-hGITR antibody-mediated activation of peripheral blood mononuclear cells (PBMC)
[0399] To test the potential activation of anti-human GITR mAbs, fresh or frozen human PBMCs from donors were evenly distributed into test tubes and incubated with anti-hGITR Ab and anti-human CD3 antibodies. The activation status of PBMCs was assessed by flow cytometry, by T cell proliferation (CellTrace Violet dye) and expression of CD25 and CD44. The presence of IL-2 was detected using ELISA.
Claims
1. An isolated defucosylated antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc) comprising an asparagine residue (N) at position 297 and a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) G236A (referred to herein as afuco-G236A).
2. An antibody that specifically binds to a glucocorticoid-induced TNFR-related (GITR) protein, wherein the antibody comprises a variable region (Fab) and a modified human IgG1 constant region (Fc), wherein the modified human IgG comprises the following amino acid substitutions: substitution of a glycine residue at position 236 by an alanine residue (G236A), substitution of an alanine residue at position 330 by a leucine residue (A330L), and substitution of an isoleucine residue at position 332 by a glutamic acid residue (I332E) (referred to herein as GAALIE).
3. The antibody according to any one of claims 1 and 2, wherein the GITR is human GITR (hGITR).
4. The antibody according to claim 3, wherein the Fab of the antibody comprises a group of 6 CDR sequences, wherein the group is selected from: i. A heavy chain (HC) CDR1 comprising the sequence GFSLSTSGMG (SEQ ID NO: 1), a HC CDR2 comprising the sequence IWWDDDK (SEQ ID NO: 2), a HC CDR3 comprising the sequence ARTRRYFPFAY (SEQ ID NO: 3), a light chain (LC) CDR1 comprising the sequence QNVGTN (SEQ ID NO: 4), a LC CDR2 comprising the sequence SAS or the sequence SAST (SEQ ID NO: 5), and a LC CDR3 comprising the sequence QQYNTDPLT (SEQ ID NO: 6); ii. a HC CDR1 comprising the sequence SYGMH (SEQ ID NO: 7), a HC CDR2 comprising the sequence VIWYEGSNKYYADSVKG (SEQ ID NO: 8), a HC CDR3 comprising the sequence GGSMVRGDYYYGMDV (SEQ ID NO: 9), a LC CDR1 comprising the sequence RASQGISSALA (SEQ ID NO: 10), a LC CDR2 comprising the sequence DASSLES (SEQ ID NO: 11), and a LC CDR3 comprising the sequence QQFNSYPYT (SEQ ID NO: 12); and iii. HC CDR1 comprising the sequence GYTFTRYW (SEQ ID NO: 25), HC CDR2 comprising the sequence IYPGDGDT (SEQ ID NO: 26), HC CDR3 comprising the sequence ARNPLTTATAWFVY (SEQ ID NO: 27), LC CDR1 comprising the sequence ENIYSN (SEQID NO: 28), LC CDR2 comprising the sequence AAT, and LC CDR3 comprising the sequence QHFWGPPWT (SEQ ID NO: 29).
5. The afuco-G236A antibody of claim 1, comprising the heavy chain sequence set forth in SEQ ID NO: 13, the light chain sequence set forth in SEQ ID NO: 14, or both.
6. The GAALIE antibody of claim 2, comprising the heavy chain sequence set forth in SEQ ID NO: 15, the light chain sequence set forth in SEQ ID NO: 14, or both.
7. The antibody according to any one of claims 1 to 6, wherein the antibody is a chimeric antibody or a humanized antibody.
8. A conjugate comprising the antibody according to any one of the preceding claims.
9. A polynucleotide sequence encoding at least one chain of the antibody or antibody conjugate according to any one of claims 1 to 8.
10. The polynucleotide sequence according to claim 9, which encodes the afuco-G236A antibody heavy chain amino acid sequence set forth in SEQ ID NO: 13 or a variant thereof having at least 90% sequence identity thereto.
11. The polynucleotide sequence of claim 9, comprising a sequence encoding an antibody heavy chain selected from SEQ ID NO: 22 and SEQ ID NO: 23, or a variant thereof having at least 80% sequence identity with the polynucleotide sequence.
12. A vector, plasmid or construct comprising at least one polynucleotide sequence according to any one of claims 9 to 11.
13. A vector, plasmid or construct according to claim 12, comprising a polynucleotide sequence encoding an antibody heavy chain selected from SEQ ID NO: 22 and SEQ ID NO: 23 or a variant thereof having at least 80% sequence identity, and a polynucleotide sequence of SEQ ID NO: 24 or a variant thereof having at least 80% sequence identity.
14. A host cell comprising at least one polynucleotide sequence according to any one of claims 9 to 11 or a vector, plasmid or construct according to any one of claims 12 and 13.
15. A composition comprising a plurality of antibody molecules that specifically bind to a glucocorticoid-induced TNFR-related (GITR) protein, wherein each antibody molecule comprises a variable region (Fab) and a modified human IgG1 Fc region, wherein the Fc region comprises an asparagine residue (N) at position 297, a substitution of the amino acid residue glycine (G) at position 236 by an alanine residue (A) (G236A), and wherein about 65-100% of the antibody molecules in the composition comprise a mature core carbohydrate structure lacking fucose attached to the asparagine residue (N) at position 297 of the Fc region.
16. The composition of claim 15, wherein about 80-100% of the antibody molecules in the composition comprise a mature core carbohydrate structure lacking fucose attached to an asparagine residue (N) at position 297 of the Fc region.
17. The composition of any one of claims 15 and 16, wherein the GITR is human GITR (hGITR).
18. The composition of claim 17, wherein the Fab of each of the antibody molecules comprises a group of 6 CDR sequences, wherein the group is selected from: i. A heavy chain (HC) CDR1 comprising the sequence GFSLSTSGMG (SEQ ID NO: 1), a HC CDR2 comprising the sequence IWWDDDK (SEQ ID NO: 2), a HC CDR3 comprising the sequence ARTRRYFPFAY (SEQ ID NO: 3), a light chain (LC) CDR1 comprising the sequence QNVGTN (SEQ ID NO: 4), a LC CDR2 comprising the sequence SAS or the sequence SAST (SEQ ID NO: 5), and a LC CDR3 comprising the sequence QQYNTDPLT (SEQ ID NO: 6); ii. a HC CDR1 comprising the sequence SYGMH (SEQ ID NO: 7), a HC CDR2 comprising the sequence VIWYEGSNKYYADSVKG (SEQ ID NO: 8), a HC CDR3 comprising the sequence GGSMVRGDYYYGMDV (SEQ ID NO: 9), a LC CDR1 comprising the sequence RASQGISSALA (SEQ ID NO: 10), a LC CDR2 comprising the sequence DASSLES (SEQ ID NO: 11), and a LC CDR3 comprising the sequence QQFNSYPYT (SEQ ID NO: 12); and iii. HC CDR1 comprising the sequence GYTFTRYW (SEQ ID NO: 25), HC CDR2 comprising the sequence IYPGDGDT (SEQ ID NO: 26), HC CDR3 comprising the sequence ARNPLTTATAWFVY (SEQ ID NO: 27), LC CDR1 comprising the sequence ENIYSN (SEQID NO: 28), LC CDR2 comprising the sequence AAT, and LC CDR3 comprising the sequence QHFWGPPWT (SEQ ID NO: 29).
19. The composition of claim 17, wherein each of the antibody molecules comprises the heavy chain sequence set forth in SEQ ID NO: 13, the light chain sequence set forth in SEQ ID NO: 14, or both.
20. The composition according to any one of claims 15-19, wherein the antibody molecule is a chimeric antibody or a humanized antibody.
21. The composition according to any one of claims 15-20, wherein the composition is in the form of a pharmaceutical composition further comprising at least one carrier, excipient or diluent.
22. A pharmaceutical composition comprising as an active ingredient at least one antibody according to any one of claims 1 to 7 or the antibody conjugate according to claim 8, and at least one carrier, excipient or diluent.
23. A pharmaceutical composition according to any one of claims 21 and 22, for use in enhancing the production of pro-inflammatory cytokines, depleting or inhibiting regulatory T cells (Tregs) or activating dendritic cells.
24. The pharmaceutical composition according to any one of claims 21 and 22, for use in enhancing the immunoco-stimulatory activity of hGITR.
25. The pharmaceutical composition according to any one of claims 21 to 24, for use in treating cancer or tumors.
26. The pharmaceutical composition for use according to claim 25, wherein the cancer is a metastatic cancer.
27. The pharmaceutical composition for use according to any one of claims 25 and 26, wherein the treatment comprises administering or performing at least one additional anti-cancer therapy.
28. The pharmaceutical composition for use according to claim 27, wherein the additional anti-cancer therapy is selected from surgery, chemotherapy, radiotherapy, immunotherapy and hormone therapy.
29. A pharmaceutical composition for use according to any one of claims 25-28, wherein the treatment results in delaying, slowing or arresting tumor growth or recurrence, or preventing or reducing the formation, growth or spread of metastases.
30. The pharmaceutical composition for use according to any one of claims 25-28, wherein the treatment results in enhanced anti-tumor effect, modulation of the tumor microenvironment, or induction of long-term anti-tumor immunity.
31. A kit comprising an antibody or antibody conjugate according to any one of claims 1-8 or a composition according to any one of claims 15-19, packaged in a packaging material and marked in a printed manner in or on the packaging material.
32. A method for producing an anti-hGITR antibody according to any one of claims 1 to 7, the method comprising: (i) transfecting a vector, plasmid or construct comprising a polynucleotide sequence encoding a heavy chain and a light chain pair into a cell; (ii) culturing a cell comprising at least one polynucleotide encoding a heavy chain or a light chain of an antibody according to any one of claims 1 to 7 under conditions that allow expression of the heavy chain and / or the light chain; and (iii) recovering the chains from the cells.
33. The method of claim 32, wherein the antibody is afuco-G236A antibody, and wherein defucosylation is performed post-translationally during the transfection step.
34. A method of treating cancer or a tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody according to any one of claims 1-7, an antibody conjugate according to claim 8, or a composition according to any one of claims 15-19.
35. A method of enhancing anti-tumor immunity in a subject in need thereof, the method comprising administering to the subject an antibody according to any one of claims 1-10, an antibody conjugate according to claim 11, or a composition according to any one of claims 15-19.
36. A method for delaying, slowing or preventing tumor growth or recurrence, the method comprising administering to the subject an antibody according to any one of claims 1-7, an antibody conjugate according to claim 8, or a composition according to any one of claims 15-19.
37. A method of reducing the formation, growth or spread of metastasis, the method comprising administering to the subject an antibody according to any one of claims 1-7, an antibody conjugate according to claim 8, or a composition according to any one of claims 15-19.
38. The method of any one of claims 34-37, wherein the cancer is a metastatic cancer.
39. The method of any one of claims 34-38, wherein the treatment of cancer or tumor comprises administering or performing at least one additional anti-cancer therapy.
40. The method of claim 39, wherein the additional anti-cancer therapy is selected from surgery, chemotherapy, radiotherapy, and immunotherapy.
41. A method of enhancing the production of proinflammatory cytokines, depleting or inhibiting regulatory T cells (Tregs), or activating dendritic cells, the method comprising administering to the subject an antibody according to any one of claims 1-7, an antibody conjugate according to claim 8, or a composition according to any one of claims 15-19.
42. A method for enhancing the immunoco-stimulatory activity of hGITR, the method comprising administering to the subject an antibody according to any one of claims 1-7, an antibody conjugate according to claim 8, or a composition according to any one of claims 15-19.
